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Liver Cancer 
Liver cancer is the fifth most common cancer and the second most common cause of 
cancer mortality worldwide. It causes over 800,000 deaths yearly and more than 560.000 
patients per year are diagnosed with primary liver cancer worldwide 1. Primary liver cancer 
has been traditionally classified into three main types based on the tumor cell type: 
hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and hepatocellular-
cholangiocarcinoma (CHC). HCC constitutes more than 85% of primary liver cancers. 
Major risk factors for liver cancer include chronic viral hepatitis (hepatitis B or C), cirrhosis, 
heavy alcohol use and nonalcoholic fatty liver disease 2. Surgical resection is the most 
optimal treatment for liver cancer. However, less than 30% of patients are eligible for 
surgical resection, because liver cancer is often detected at a late stage. Liver 
tranplantation has also been established as an effective therapy for liver cancer 3. 
However, the major limitations of liver tranplantation are: 1) the shortage of deceased 
donor living grafts; 2) the strict criteria for selecting patients which are eligible for 
transplantation; 3) the immunosuppression treatment after liver transplantation weakens 
the immune system and increases the risk of tumor recurrence or de novo formation of 
different types of cancers. In addition, tumor recurrence is the leading cause of death 
following surgery and the frequency of recurrence is up to 85% within 5 years. For 
advanced HCC, the only FDA approved drug for treating liver cancer is Sorafenib, which 
extends the survival time of patients for approximately 3 months. Thus, understanding the 
biology and investigation of effective treatment is urgently needed for liver cancer.  
 
Stem cells in liver homeostasis, injury and carcinogenesis  
Liver stem cells are defined by their ability to self-renew and differentiate into both 
hepatocytes and cholangiocytes. The various functions of liver stem cells are distinct in 
two aspects: 1) those involved in homeostatic maintenance of the liver compartment under 
normal physiological conditions; 2) those involved in tissue repair/regeneration under 
pathological conditions.  
During homeostasis, liver stem cells remain quiescent and possess a longer life span 
compared to the rest of the cells. Classically, the quiescent/slow cycling cells are identified 
by nucleotide analogs (thymidine or BrDU)-dependent label retaining assays. Different 
locations in liver have been reported to contain stem cells by virtue of their capacity to 
incorporate and retain label in such assays. These regions include the canals of Hering, 
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the bile duct and the peribiliary area 4. Upon liver injury, liver stem cells start to proliferate 
and then further differentiate. For example, the leucine-rich-repeat-containing G-protein-
coupled receptor 5 (LGR5) marks a stem cell pool which actively proliferates upon carbon 
tetrachloride (CCL4)-induced liver injury 5. Isolated LGR5 stem cells can give birth to both 
cholangiocyte and hepatocyte population in vitro. The tranplantation of single LGR5+ cell 
derived organoid can generate functional hepatocytes in liver function-impaired mice. 
However, chronic liver injury can eventually result in the development of liver cancer, 
possibly because the injury is also accompanied by long-term activation and expansion of 
stem cells. This has led to the notion that adult stem cells can accumulate 
genetic/epigenetic changes and subsequently contribute to tumor initiation and 
progression and this concept has attracted great interest. Because various mutations are 
necessary for a cell finally turning into cancerous entity, the long-lived and injury-activated 
stem cells have the highest opportunity to accumulate those cancer-inducing mutations 
over years. For example, the sex determining region Y-box 9 (SOX9) gene has been 
demonstrated to be a marker for facultative stem cells in liver 6. SOX9 liver cells can 
compensate for the loss of bulk of hepatocytes in several liver injury settings, including 
CCL4 or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) induced liver injury, as well as 
choline-deficient ethionine supplemented (CDE) diet. However, liver SOX9 expressing 
cells are present in HCC 7, which is the most common type of primary liver cancer. The 
prognosis of HCC patients correlates to the expression profile of SOX9. Thus, it would be 
particularly interesting to investigate the dynamics of liver stem cells under normal 
physiological and different pathological conditions.  
 
Cancer stem cells  
The definition of cancer stem cell is “a cell within a tumor that possesses the capability to 
self-renew and to cause the heterogeneous lineages of cancer cells that comprise the 
tumor” 8. Cancer stem cells are considered to be responsible for tumor initiation and 
growth, failure of treatment and tumor recurrence. Functionally, the colony formation and 
therapy resistance assay are classical and convenient approaches to identify the tumor 
stem cell in vitro. Genetic lineage tracing and limited diluted tumor formation assay are 
used to demonstrate tumor stemness in vivo. For instance, LGR5 marks a cancer stem 
cell population in intestinal and colorectal carcinoma 9-11. LGR5 tumor stem cells are highly 
tumorigenic, and can form tumor when only 100 cells were transplanted into 
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immunocompromised mice 12. In addition, LGR5+ cancer stem cells play a critical role in 
the development and maintenance of colorectal cancer derived metastasis 12. Thus, the 
investigation of cancer stem cells would provide new insights with respect to the 
understanding the biology of the tumor, as well as allow for the discovery of more effective 
therapy.  
 
Organoids: an innovative model for studying (cancer) stem cells.  
Organoids are stem cell derived, organ-like 3D structures, which have attracted great 
attention during the recent years. Stem cells are isolated from a particular organ/tissue 
proliferate and then arrange themselves automatically into a 3-dimensional structure in 
appropriate culture conditions. The resulting structures contain different cell types which 
also existed in the original corresponding organ/tissue, where those stem cells derived 
from. This technique has subsequently been adapted to culture organoids from the 
intestine 13, liver 5, stomach 14, 15 and prostate 16.  
Organoid systems offer one of the most promising platforms for harnessing stem cell 
research. With respect to regenerative medicine for treating liver disease, material suitable 
for therapeutic transplantation is always rare, leading to an urgent requirement for 
developing alternative sources. Human liver organoid have been successfully transplanted 
into the immunodeficient mouse to compensate for the insufficient liver function 14. 
Although extensive investigation is required before clinical application can become 
commonplace, especially considering the technical, safety, efficacy and ethical issues, 
organoid-based stem cell therapy does provide a new avenue for transplantation medicine.  
Organoid system can also be used for modelling different diseases, including infectious 
disease, genetic disease, especially different types of cancers. Organoids have already 
been successfully established from primary tumor of colons 13, stomach 14, prostate 17 and 
pancreas 18. There are many advantages of tumor organoid models, but just to highlight a 
few as following: 1) understanding for the impact of a specific genetic mutation, by 
combining with the CRISPR/Cas9 genome editing and xenograft/allograft tranplantation 
assays; 2) allowing the culturing of both primary tumor and tumor surrounding healthy 
tissue, thus providing personalized information regarding response to therapy ex vivo 19, 20; 
3) an innovative model system for studying cancer stem cells 12. In sum, organoid system 
representing an unique tool for the research field to advance in-depth research of adult 
stem cells, cancers and cancer stem cells. 
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Cancer stem cell-targeted therapy  
Cancer stem cells have been hypothesized to fuel the growth of the tumor by giving birth 
to offspring that retains the cancer stemness , as well as proliferative progenitor cells that 
mediate compartment expansion. They are also thought to be resistant to treatment, and 
thus responsible to the recurrence of the tumor following therapy. These features make 
cancer stem cells as attractive cancer targets 21. 
Over the past decades, several cancer stem cell markers have been identified as 
potential therapeutic targets 21. For example, targeting LGR5 colon cancer stem cells has 
been investigated, by using colorectal mouse cancer model, as well as xenograft cancer 
model 12, 22. Those investigations employed the diphtheria toxin-diphtheria toxin receptor 
(DT-DTR) system, which can specifically ablate LGR5-expressing cells. The depletion of 
LGR5 colon cancer stem cell were observed to impede the growth of the primary tumor, as 
well as the metastasis.  
However, many cancer stem cell markers are also expressed in the normal stem cells or 
embryonic stem cells. Thus, it is very important to selectively target tumor stem cells, 
without compromising normal stem cell homeostasis. Thus, researchers have adopted 
antibody-drug conjugates (ADCs) and assessed the resulting tumor-targeting efficiency, as 
well as their safety in vivo. The anti-LGR5-antibody-drug conjugates are reported to inhibit 
the tumor growth effectively, and even improve the survival for the intestinal cancer 
carrying mouse. Impressively, the anti-LGR5-antibody-drug conjugate has no major effect 
on the normal stem cell pool 10. Thus, It will be of particular interesting to further explore 
novel strategies to target cancer stem cells. 
 
Aim of this Thesis 
Based on the former, the general aims of this thesis are: 1) to investigate the dynamics of 
LGR5 proliferative stem cells in homeostatis and injury of the liver, and to characterize the 
role of LGR5 stem cell in maintenance of the stem cell pool ex vivo. 2) to demonstrate the 
existence and function of quiescent stem cells using the long-term label retaining assay 3) 
to investigate the interrelationship of the proliferative LGR5 stem cells and the quiescent 
stem cell during liver homeostasis and injury. 4) to establish malignant organoid models 
from mouse primary liver tumors and demonstrate their applications in liver cancer 
research. 5) to investigate the existence and function of liver cancer stem cells by adopting 
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transgenic mouse model and 3D organoid model. 6) to investigate whether normal LGR5 
proliferative stem cells participate in the tumor progression and formation by using LGR5 
lineage tracing mouse.  The results provide a wealth of data on the action and function of 
the LGR5 stem cell compartment and other stem cell compartment in hepatic physiology 
and pathology. 
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Abstract: 
Background & Aims: Adult liver stem cells are usually maintained in a quiescent/slow 
cycling state. However, a proliferative population, marked by leucine-rich repeat-containing 
G-protein coupled receptor 5 (LGR5), was recently identified as an important liver stem 
cell population. We aimed to investigate the dynamics and functions of proliferative and 
quiescent stem cells in healthy and injured livers. 
 
Methods: We studied LGR5-positive stem cells using diphtheria toxin receptor (DTR) and 
green fluorescent protein (GFP) knock-in mice. In these mice, LGR5-positive cells 
specifically co-express DTR and the GFP reporter. Lineage tracing experiments were 
performed in mice in which LGR5-positive stem cells and their daughter cells expressed a 
YFP/mTmG reporter. Slow-cycling stem cells were investigated using GFP-based, Tet-on 
controlled transgenic mice. We studied the dynamics of both stem cell populations during 
liver homeostasis and injury induced by carbon tetrachloride. Stem cells were isolated 
from mouse liver and organoid formation assays were performed. We analyzed hepatocyte 
and cholangiocyte lineage differentiation in cultured organoids. 
 
Results: We did not detect LGR5-expressing stem cells in livers of mice at any stage of a 
lifespan, but only following liver injury induced by carbon tetrachloride. In the liver stem cell 
niche, where the proliferating LGR5+ cells are located, we identified a quiescent/slow-
cycling cell population, called label-retaining cells (LRCs). These cells were present in the 
homeostatic liver, capable of retaining the GFP label over 1 year, and expressed a panel 
of progenitor/stem cell markers. Isolated single LRCs were capable of forming organoids 
that could be carried in culture, expanded for months, and differentiated into hepatocyte 
and cholangiocyte lineages in vitro, demonstrating their bona fide stem cell properties. 
More interestingly, LRCs responded to liver injury and give rise to LGR5-expressing stem 
cells, as well as other potential progenitor/stem cell populations, including SOX9- and 
CD44-positive cells. 
 
Conclusions: Proliferative LGR5 cells are an intermediate stem cell population in the liver 
that emerge only during tissue injury. In contrast, LRCs are quiescent stem cells that are 
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present in homeostatic liver, respond to tissue injury, and can give rise to LGR5 stem cells, 
as well as SOX9- and CD44-positive cells. 
 
Keywords: Liver Stem Cells; LGR5; Quiescent Stem Cells; Proliferative Stem Cells 
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Introduction  
In general, adult stem cells are maintained in quiescence at homeostatic conditions but 
are able to exit the quiescent state and rapidly expand and differentiate in response to 
tissue injury.1 Counterintuitively, recent studies indicated that LGR5, as a component of 
the Wnt signaling pathway, robustly marks actively dividing stem cells in the gut,2 
stomach,3 hair follicle,4 mammary gland5 and liver.6 
In the intestine, proliferative LGR5+ stem cells are present throughout the intestine and 
populate the crypt and villi within 3 days.2, 7 Another type of stem cells, marked by BMI1, 
represent a rarer cell population that are quiescent but can be activated under pathological 
conditions and give birth to proliferative LGR5+ cells in the intestine.8 
In the liver, the early streaming liver theory has proposed that normal liver turnover is 
originated from the portal zone and migrates towards the central vein, mainly driven by 
mature hepatocyte proliferation.9, 10 Liver stem cells, as a small population of cells, are 
thought to reside around the portal zone and maintained in quiescence.11 As an emerging 
field, a recent study reported that an Axin2 marked population of proliferating and self-
renewing cells adjacent to the central vein can also contribute to generation of new 
hepatocytes.12 Upon tissue injury, in particular in the setting of chronic liver diseases, long-
term (10-30 years) chronicity triggers continuous inflammation, liver regeneration and 
possible development of liver cancer which coordinately initiate the activation and 
expansion of hepatic stem cells, though recent studies in experimental models have 
indicated that hepatocytes are probably the main cell-of-origin in liver canecr.13-16 In fact, 
this proposed quiescent liver stem cell population has not been functionally demonstrated 
yet; whereas the proliferative LGR5+ liver stem cells have been recently identified. These 
LGR5+ stem cells were activated upon carbon tetrachloride (CCl4) induced injury in a Lgr5-
lacZ knock-in mouse model. Single isolated LGR5+ cells can initiate organoids ex vivo. 
Upon transplantation, those organoids can repopulate the injured liver of the 
fumarylacetoacetate hydrolase mutant mice.6  
Previously, the liver quiescent/slow-cycling cell population, also termed as label 
retaining cells (LRCs), was identified by labeling with nucleotide analogs that incorporate 
into genomic DNA in mice.11 However, this classical approach was not able to functionally 
characterize these cells due to technical limitations. In this study, we applied a green 
florescent protein (GFP) based, Tet-on controlled transgenic mouse model that enables us 
to identify, isolate and functionally study these liver LRCs. Secondly, we have investigated 
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the interrelationship of the proliferative LGR5 stem cells and the LRCs during liver 
homeostasis and injury.  
 
 
Materials and Methods: 
Tamoxifen (TAM) Labelling Experiments 
    Lgr5-creERT2 mice (kindly provided by Genentech)8 were crossed with B6.129X1-
Gt(ROSA)26Sortm1(EYFP)Cos/J (Rosa26-YFP, The Jackson Laboratory) and 
Gt(ROSA)26Sortm4 (ACTB-tdTomato,-EGFP)Luo/J (Rosa26-mTmG, The Jackson 
Laboratory)17 Cre reporter mice respectively. Offspring (8-12 weeks) were administrated 
with single or weekly repeated intraperitoneal (i.p.) CCl4 injection (10 μL/20 g body weight 
of 10% CCl4 solution in corn oil or corn oil as control). A single dose of TAM (5 mg per 
mouse) was i.p. injected 5 days after the last CCl4/oil injection for initiating lineage tracing. 
Mice were sacrificed at post day 5 and 25 of TAM injection, and tissues were collected for 
analyzing the presence of daughter cells derived from LGR5+ cells. For Rosa26-YFP 
reporter mice, the daughter cells derived from LGR5+ cells expressed yellow florescent 
protein (YFP); For Rosa26-mTmG reporter mice, regular cells expressed membrane-
targeted tandem dimer Tomato florescent protein (mT), but the offspring derived from 
LGR5+ cells expressed membrane-targeted green fluorescent protein (mG).  
 
Diphtheria Toxin (DT) Cell Ablation 
    Lgr5-DTR-GFP transgenic mice (kindly provided by Genentech)8 specifically co-express 
the diphtheria toxin (DT) receptor (DTR) and GFP under the control of the Lgr5 promotor. 
Thus, LGR5+ cells will be marked by GFP, and LGR5-GFP+ cells can be selectively 
ablated by treatment with DT. To deplete LGR5-GFP+ cells in cultured organoids, DT 
(concentrations ranged from 1 ng/ml to 100 ng/ml) was added it to organoid expansion 
medium for three days, followed by further analysis or passage.18 For organoid initiation 
assay, DT was supplied constantly with organoid initiation medium since organoids were 
seeded.  
 
In vivo Label Retaining System  
    The transgenic mouse model expressing the reverse tetracycline transactivator (rtTA) 
under a particular promoter (Cag promoter; Rosa26 promoter; HnRNP promoter) was 
mated with tetO-HIST1H2BJ/GFP (H2BGFP) mice (JAX laboratory), which carried a 
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Histone2B fused GFP protein (H2B-GFP) under control of a TetO-responsive promoter.19-
21 Young adult transgenic mice (4-6 weeks of age) carrying heterozygous rtTA/H2BGFP 
and control littermates were administered with doxycycline (dox, Sigma-Aldrich) at 1 mg/ml 
in 5% sucrose (Sigma-Aldrich) containing drinking water for 7 days. GFP will be expressed 
upon dox administration, in all cells of the mice which have the corresponding promoter 
(Cag/Rosa26/HnRNP promoter). After withdrawing the dox water, GFP will not be 
produced anymore and proliferating cells will progressively dilute the GFP, but 
quiescent/slow cycling cells can retain the GFP label. GFP expression in mice was 
analyzed from 0 till 65 weeks after dox induction. All animal experiments were approved by 
the Committee on the Ethics of Animal Experiments of the Erasmus Medical Center. 
 
 
Results 
LGR5+ Stem Cells Are Absent in the Homeostatic Liver Over the Life Span of 
a Mouse, But Emerge Upon Injury 
A previous study has reported the activation of liver LGR5 proliferative stem cells by 
CCl4 induced injury.
6 By adopting Lgr5-DTR-GFP knock-in mice,8 we observed that LGR5-
expressing cells (marked by GFP) are absent in the homeostatic liver over the life span of 
a mouse (Supplementary Figure 1A). Indeed, single/repeated administration of CCl4 for 
inducing acute/chronic hepatic injury triggered the emergence of LGR5-GFP+ cells (mean 
± SEM, 1 × CCl4: 0.02 ± 0.01%, n = 3; 4 × CCl4: 0.04 ± 0.01%, n = 3; 17 × CCl4: 0.11 ± 
0.01%, n = 4) in the liver (Supplementary Figure 1B-D, and Supplementary Figure 2: 
immunohistochemistry). Isolated single LGR5-GFP+ cells derived from 4 months of 
chronically injured livers formed organoids with the ability of serial passage 
(Supplementary Figure 1E). Meanwhile, we found that LGR5-GFP- cells also formed 
organoids with the ability of serial passage, although with a lower organoid initiation 
efficiency compared to LGR5-GFP+ cells (Supplementary Figure 1F-G). 
We further investigated the daughter cells (marked by YFP) derived from LGR5-
expressing cells by Lgr5-CreERT2/Rosa26-YFP lineage tracing mice (Supplementary 
Figure 3A-B).8 Upon acute liver injury, less than 0.05% or 0.1% of liver cells during a 5-day 
or 25-day lineage tracing period were labelled with YFP, respectively. Even when CCl4 
was administrated for 4 months (17 × CCl4) to induce chronic injury, there was still a very 
low percentage of YFP-expressing cells (less than 0.2%) identified in the liver 
(Supplementary Figure 3C-E). To further confirm and better visualize LGR5 daughter cells, 
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we next employed a mTmG reporter mouse for LGR5 lineage tracing (Supplementary 
Figure 3F).17 Due to the specific membrane localization of fluorescent protein in the mTmG 
reporter mice, the daughter cells of LGR5 stem cells were clearly visible both in liver as 
well as the intestine. After using the same acute injury and lineage tracing strategy as 
mentioned above, we confirmed the low percentages of LGR5 offspring contributing to 
injury recovery in the liver, both in 5-day and 25-day lineage tracing period (Supplementary 
Figure 3G, and Supplementary Figure 4: immunohistochemistry). Our results indicated that, 
unlike other progenitor/stem cells (e.g. Sox9+ cells),22 hepatic LGR5 stem cells contribute a 
relatively low number of daughter cells to injury recovery of the liver.  
 
Bile Duct Gives Birth to LGR5+ Stem Cells, and LGR5 Cells Are Dispensable 
for Organoid Formation  
Since we and others6 have observed that LGR5-expressing cells are present around or 
within the bile duct of the portal triad area (Figure 1A, and Supplementary Figure 2B-C), 
we asked whether bile duct indeed gives rise to LGR5+ liver stem cells. Therefore, we first 
isolated bile ducts (no LGR5+ cells) from the liver of the healthy Lgr5-DTR-GFP mice and 
seeded the bile ducts in matrigel for organoid initiation (Figure 1B and D). We found that 
LGR5-GFP+ cells emerged during organoid initiation and were stably maintained during 
organoid expansion (Figure 1C and E), indicating that bile duct can give rise to LGR5+ 
cells. Furthermore, both LGR5-GFP+ and LGR5-GFP- cells dissociated from bile duct 
derived organoids and isolated by FACS sorting can re-initiate organoids. LGR5-GFP+ 
cells were maintained in the organoids derived from LGR5-GFP+ cells, but also appeared 
in the organoids formed by the LGR5-GFP- cells (Figure 1F and G).  
We further investigated whether the depletion of LGR5-expressing cells will affect 
organoid expansion. Since the Lgr5-DTR-GFP mice co-express DTR, LGR5-GFP+ cells 
can be selectively ablated by treatment with DT (Figure 1H and I). We first found that 1 
ng/ml of DT was sufficient to specifically kill LGR5+ cells (Figure 1J and Supplementary 
Figure 5A). Interestingly, specific ablation of LGR5+ cells by DT did not strongly affect the 
growth of formed organoids (Figure 1K). LGR5-depleted organoids can still be passaged, 
with similar efficiency of re-initiating organoids, compared to organoids containing LGR5+ 
cells (control vs. DT treatment: 3.30 ± 1.33% vs. 3.07 ± 0.70%, mean ± SEM, n = 3; P = 
NS) (Figure 1L).  
To further investigate whether the depletion of LGR5-expressing cells will affect 
organoid initiation, we supplied the organoid culture medium with DT since the initial 
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culture of isolated bile ducts (Figure 1M). No clear difference of organoid morphology was 
observed between DT treated and untreated groups. FACS analysis confirmed the efficient 
ablation of LGR5-expressing cells (Figure 1O, and Supplementary Figure 5B). Organoids 
derived from wild type mouse were taken as control and also showed similar results 
(Figure 1P, and Supplementary Figure 5C-D). Furthermore, organoids of the DT treated 
group could be weekly passaged for more than 2 months with the persistent supplement of 
DT. The DT treated group showed similar organoid re-initiation efficiency, compared to the 
untreated group (Figure 1N). Interestingly, the LGR5-depleted organoids showed 
significant upregulation of a panel of progenitor/stem cell markers, including Oct4, Sox2, 
Cd44, Cd133, Sox9, Lrig1 and Mex3a, suggesting a possible compensatory mechanism 
(Figure 1Q). Thus, these data suggest that bile ducts harbor an early stem cell population 
that can give rise to LGR5+ stem cells, but liver LGR5+ cells are dispensable for organoid 
initiation and further expansion.  
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Figure 1. Bile ducts could give birth to LGR5 stem cells which were dispensable for organoid 
initiation and expansion. (A) LGR5 stem cells (green) localized around the portal triad, which 
indicated by anti-GFP immunofluorescence staining; Red arrow: LGR5+ cell. DAPI: blue; LRCs: 
Green. (B) An outline of the experimental strategy used. (C) Representative pictures showing bile 
ducts derived organoids containing LGR5-expressing cells; Red arrow: LGR5+ cell. (D-G) Bile duct 
isolated from healthy Lgr5-DTR-GFP mice and initiated organoids ex vivo. Then, LGR5-GFP+ and 
LGR5-GFP- cells were isolated from organoids by FACS sorter for further organoid initiation. 
Representative flow cytometry plots show that bile duct (D) can give rise to LGR5+ stem cells (E), 
LGR5-GFP+ stem cells could give rise to both LGR5-GFP+ and LGR5-GFP- cells (E, F), and LGR5-
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GFP- cells could give birth to LGR5-GFP+ cells (E, G). (H) A schematic of the Lgr5-DTR-GFP 
transgenic mouse model used. (I) Bile ducts isolated from Lgr5-DTR-GFP mice initiated organoids 
and were further treated with DT for LGR5 depletion as indicated in the scheme. (J) DT efficiently 
depleted LGR5-GFP+ cells (n = 3, *P < .05). (K) Representative microscopic pictures of control 
(CTR) and LGR5 depleted (DT) organoids. Original magnifications were ×40. (L) LGR5-depleted 
organoids showed similar re-initiating efficiency compared to control group (n = 3, P = NS. NS: not 
significant). (M) Bile ducts isolated from Lgr5-DTR-GFP transgenic mice were directly treated with 
DT to initiate organoids as indicated in the scheme. (N) The organoid re-initiation efficiency for 
control and LGR5 depleted groups (n = 21, P = NS. NS: not significant). (O) Depletion of LGR5 
stem cells did not influence organoid initiation. Representative flow cytometry (Left panel) and 
microscopic pictures for control and LGR5 depleted organoids, at post Day 2 (Middle panel) and 
Day 4 (Right panel) of DT treatment. CTR: control, without adding DT. Original magnifications were 
×40 (n = 3). (P) DT treatment did not affect the initiation of organoids derived from wild type mouse 
livers (n = 3). (Q) Progenitor markers were upregulated upon LGR5 depletion (n = 3, *P < .05). 
 
Identification of Label Retaining Cells (LRCs) within the LGR5+ Stem Cell 
Niche in the Liver 
An intriguing question is the origin of these proliferative LGR5+ stem cells in the liver. 
We hypothesize that within the same niche there may be an earlier-stage but quiescent 
stem cell population, which permanently resides there, but becomes activated during injury 
and gives rise to LGR5+ cells. Although the classical Bromodeoxyuridine (BrdU) labeling 
technique has been used to identify slow-cycling cells in the portal triad area,23 these cells 
have not been functionally confirmed due to the intrinsic limitations of this approach, i.e. 
Brdu cannot incorporate into fully quiescent populations and the labeled cells cannot be 
isolated for functional characterization.  
To overcome these limitations, we employed a cell cycle independent approach, i.e.in 
vivo pulse-chase labeling with H2B-GFP to identify quiescent/slow-cycling cells.19 This 
rtTA/Tet-on-H2BGFP system conditionally expresses H2B-GFP only in the presence of 
dox. Adopting 7 days of dox induction followed by a long term chasing period, we expect to 
be able to identify quiescent/slow-cycling cells that retain GFP fluorescence over time in 
the liver (Supplementary Figure 6A-B).  
To obtain an optimal label retaining mouse line, we first crossed Tet-on-H2BGFP 
transgenic mice with three different promoter controlled rtTA mouse lines: Cag-rtTA, 
HnRNP-rtTA and Rosa26-rtTA. Upon 7-day dox induction, the Cag-rtTA/GFP, HnRNP-
rtTA/GFP and Rosa26-rtTA/GFP mouse lines achieved 80%, 65% and 55% of GFP 
positivity in the liver respectively, which was confirmed by both FACS and 
immunofluorescence (Supplementary Figure 6C-D). Both HnRNP-rtTA/GFP and Rosa26-
rtTA/GFP mouse lines showed limited GFP induction in cholangiocyte areas 
(Supplementary Figure 6C: middle and right panels). In contrast, the Cag-rtTA/GFP 
transgenic mouse showed no leaky expression without dox (Figure 2A: 
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immunohistochemistry, Figure 2E: immunofluorescence) and high labeling efficiency both 
in the hepatocyte and cholangiocyte compartment upon dox induction (Figure 2B: 
immunohistochemistry, Figure 2F and left panel of Supplementary Figure 6C: 
immunofluorescence). Thus, the Cag-rtTA/GFP transgenic mouse line was used for further 
experimentations because of its highest induction efficiency.  
To investigate label fading during the chasing period, we first checked GFP expression 
post-dox induction from months 0 to 7. We observed that most of the liver cells gradually 
lost the GFP label, confirmed by FACS, immunofluorescent and immunohistochemistry 
staining (Supplementary Figure 7, Figure 2B-D and 2F-H). As expected, the 
immunofluorescence based on GFP expression was much more sensitive, compared to 
the anti-GFP immunohistochemistry staining; whereas immunohistochemistry provided 
much better histology. At post-dox induction of five months, GFP-retaining cells (named as 
label retaining cells, LRCs) were localizing around the portal triad (Figure 2C and G). Of 
those, around 66% (128 out of 194) were close to the portal vein (PV), but not to the 
central vein (CV). This localization became much clearer at months 6-7 (83%, 200 out of 
240). qRT-PCR revealed that LRCs compared with non-LRCs expressed higher levels of 
Ck19 (Figure 2I), but not Hnf4ɑ (Figure 2J). After further staining with cholangiocyte 
marker CK19, we found that around 32% LRCs expressed CK19 (133 out of 344) (Figure 
2K). In contrast, no LRCs (0 of 338) expressed hepatocyte marker HNF4ɑ (Supplementary 
Figure 8). Thus, these results revealed that LRCs are localized around or within the bile 
duct structure.  
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Figure 2. Localization and characterization of liver LRCs. (A) Representative anti-GFP 
immunohistochemistry pictures showing that the rtTA/GFP mice liver did not have leaky expression 
of GFP. Left panel: negative control for GFP staining; Right panel: the anti-GFP staining of 
rtTA/GFP mice liver without dox induction. PV: portal vein. (B-D) Representative 
immunohistochemistry pictures showing GFP label immediately after dox induction (B), post 
induction month 5 (C) and month 7 (D). Red arrows: LRCs. (E-H). Representative 
immunofluorescence pictures showing that the rtTA/GFP mice liver did not have leaky expression 
of GFP (E) and expressed GFP label immediately after dox induction (F), post induction month 5 
(G) and month 7 (H). Yellow arrows: LRCs. (I-J) LRCs and non-LRCs were isolated from normal 
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mouse liver by FACS sorter and RNA was isolated directly. Gene expression quantified by qRT-
PCR showed that non-LRCs expressed higher levels of Hnf4ɑ and lower level of Ck19, compared 
to LRCs. Values were normalized against Gapdh expression (n = 3, **P < .01). (K) Representative 
confocal images for the expression of cholangiocyte marker CK19 in LRCs. CK19: red; DAPI: blue; 
LRCs: Green. 
 
LRCs Are Bona Fide Stem Cells with Capability of Initiating Organoids 
To functionally prove whether LRCs are stem cells, organoid initiation assays were 
performed. After 3-7 months of chasing, both LRCs (GFP+) and non-LRCs (GFP-) were 
isolated from the digested liver by FACS sorting. A sorting strategy by combining 
Propidium Iodide (PI) and CD45 staining was used to exclude dead cells and immune cells 
(Figure 3A). Excitingly, freshly isolated single LRCs initiated organoids with a efficiency of 
0.09 ± 0.03% (mean ± SEM, n = 5) after seeding in matrigel; whereas the non-LRCs did 
not form any organoid (Figures 3B and Supplementary Figure 9A). Since we found that 
LRCs are present around or within the bile duct structure, to further characterize LRCs, we 
also performed the organoid initiation assay for bile duct derived LRCs and non-LRCs 
(Figure 3C). The duct derived LRCs also showed higher organoid initiation ability 
compared to duct non-LRCs, and higher efficiency compared to LRCs isolated from the 
entire liver (Duct-LRCs: 0.50 ± 0.14%; Duct-Non-LRCs: 0.02 ± 0.015%: mean ± SEM, n = 
3.) (Figure 3D and E, and Supplementary Figure 9B). Those LRCs-derived organoids can 
be maintained over eight months with in expansion culture medium, by weekly passaging 
at 1:2-1:4 ratio.  
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Figure 3. Liver LRCs were able to initiate organoids. (A) The sorting strategy of LRCs. (B) Serial 
images showing the outgrowth of a single LRC. Original magnifications were ×100. (C) Transgenic 
Cag-rtTA/GFP mice were fed with dox water to induce H2BGFP expression for one week, before 
cessation of 3-7 month for chasing as indicated in the scheme. Then, bile ducts were isolated and 
digested into single cell suspension, for further duct-LRCs/non-LRCs isolation. (D) The organoid 
initiation efficiency of LRCs and non-LRCs from homeostatic liver, isolated from bile duct (n = 3, *P 
< .05). (E) The organoid initiation efficiency comparison between entire liver isolated LRCs and bile 
duct isolated LRCs (*P < .05). 
 
Extremely Quiescent Cells Retaining the Label Over One Year Have Strong 
Stem Cell Characteristics 
To further investigate the existence of extremely quiescent cells, we carried the H2B-
GFP dependent pulse-chase experiment up to 15 months. Surprisingly, a very small 
proportion of cells persistently retained the label (0.68 ± 0.20%, mean ± SEM, n = 3). To 
better visualize GFP, we stained these LRCs with an anti-GFP antibody. We found that 
these long-term LRCs are also localized within the bile duct structure (Figure 4A). We next 
isolated the bile ducts and determined the percentage of LRCs. FACS analysis confirmed 
the significant enrichment of LRCs in bile duct structure (7.31 ± 1.37%, mean ± SEM, n = 3) 
(Figure 4B). 
Functionally, LRCs exerted significantly higher organoid initiation ability compared to 
non-LRCs (Figure 4C and D, and Supplementary Figure 9C and D). These LRC-derived 
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organoids have been maintained over three months as tested so far. Compared to LRCs 
detected after 5 months of chasing, these extremely quiescent cells expressed higher 
levels of progenitor/stem cell markers, including Sox2, Oct4, Lrig1, Cd44, Mex3a and Bmi1 
(Figure 4E). Thus, these results revealed that the liver harbors extremely quiescent cells 
with strong stem cell characteristics.  
Furthermore, isolated LRCs (identified from month 3-15 post dox induction) expressed 
higher levels of a panel of stem/progenitor cell markers, including, Sox9, Nanog, Lrig1, 
Tert and Mex3a, when compared to non-LRCs (Figure 4F, Supplementary Figure 10). 
Interestingly, a set of stem cell markers, including Lgr5, Sox9, Cd133 and Cd44 (Figure 
4G), were absent or lowly expressed in the initial isolated LRCs, but emerged during 
organoid formation. We further confirmed the protein expression of CD44 and SOX9 in the 
organoid initiated by LRCs derived from healthy liver by immunofluorescent staining 
(Figure 4H-I). These results indicate that quiescent LRCs can give birth to other types of 
potential progenitor/stem cells during ex vivo expansion. 
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Figure 4. Characterizing the extremely quiescent cells that retain the GFP label over one year. (A) 
Representative confocal images showing long-term LRCs (stained with anti-GFP antibody) 
localized around portal triad, at month 15 post GFP fading. DAPI: blue; LRCs: Green. (B) 
Comparison of the percentages of entire liver and bile duct isolated LRCs (n = 3, *P < .05). (C) 
Representative images showing the outgrowth of a single LRC. Original magnification was ×100. 
(D) The organoid initiation efficiency of LRCs and non-LRCs from homeostatic liver, isolated from 
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entire liver (n = 4, *P < .05). (E) Freshly isolated LRCs derived from post dox induction month 15 
compared to month 5 expressed higher levels of progenitor/stem cell markers, as quantified by 
qRT-PCR. Values were normalized against Gapdh expression (*P < .05, n = 3). (F) LRCs (freshly 
isolated, from month 3-15) were enriched of a particular panel of progenitor markers, compared to 
non-LRCs (*P < .05; **P < .01; n = 6). (G) Compared to freshly sorted LRCs (S) from normal mice 
livers, gene expression quantified by qRT-PCR showed that LRCs derived organoids (O) 
expressed higher levels of a particular set of progenitor/stem cell markers (*P < .05; n = 6). (H-I) 
LRCs derived organoids expressed CD44 (H) and SOX9 (I). DAPI: Blue; CD44: yellow; SOX9: red. 
Yellow arrow: LRCs expressed CD44/SOX9 protein. 
 
LRCs Can Differentiate Towards Hepatocyte and Cholangiocyte Lineages 
To further investigate the lineage differentiation ability of LRCs, as one of the stem cell 
properties, we performed hepatocyte and cholangiocyte differentiation assays. By 
switching to a hepatocyte-fate differentiation medium, these organoids were differentiated 
towards hepatocyte-like cells. Upon hepatic differentiation, the progenitor/stem cell 
markers were downregulated (Figure 5A, and Supplementary Figure 11A-B); whereas the 
hepatocyte marker Hnf4a, the essential liver maturation genes (Pparg) and mature 
hepatocyte markers (Cyp3a11, Fah, Albumin and G6pc) showed trends of upregulation 
after differentiation (Figure 5B). Immunofluorescent staining confirmed that Albumin and 
HNF4ɑ proteins were expressed in over 35% (81 out of 208) and over 7% (34 out of 458) 
of the differentiated organoid cells, respectively (Figure 5E-F). In contrast, undifferentiated 
organoids did not express HNF4ɑ and Albumin protein during the expansion phage (Figure 
5E-F: upper panel). The differentiated cells also displayed larger nuclei, as a hepatocyte 
characteristic, compared to undifferentiated organoid cells (Figure 5H).  
During this differentiation process, we also observed significant upregulation of 
cholangiocyte markers, including Ck7 and Ck19 (Figure 5C). Thus, we next adopted a 
cholangiocyte-directed differentiation protocol to enhance cholangiocyte-fate differentiation. 
After switching the medium, cholangiocyte markers including Ck19, Ck7, Muc5ac and 
Muc1 were significantly upregulated (Figure 5D). The expression of CK19 was also 
validated at the protein level by immunofluorescent staining (Figure 5G). In contrast, the 
progenitor/stem cell markers, including Lgr5, Sox9, Sox2, Nanog, Sox17 and Cd44 were 
downregulated (Supplementary Figure 12). These results demonstrated that LRC stem 
cells have the potential of differentiating towards both hepatocyte and cholangiocyte 
lineages. 
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Figure 5. LRCs could differentiate towards hepatocyte and cholangiocyte lineages. (A-D) Gene 
expression of progenitor/stem cell, hepatocyte and maturation markers in LRCs derived organoids, 
compared between expansion and differentiation phase. E: expansion. HD: hepatocyte directed 
differentiation. CD: cholangiocyte directed differentiation. Values were normalized against Gapdh 
expression (*P < .05; **P < .01; ***P < .001; n = 4). (E-F) Representative confocal images for 
hepatocyte-specific markers: ALB (E, red) and HNF4ɑ (F, yellow). Upper panel: LRCs derived 
organoids in expansion medium. Middle and lower panel: LRCs derived organoids in hepatocyte 
differentiation medium. Yellow arrow: cells which expressed ALB/HNF4ɑ protein. (G) 
Representative confocal images for a cholangiocyte-specific marker, CK19 (red). Upper panel: 
LRCs derived organoid in expansion medium. Middle and lower panels: LRCs derived organoid in 
cholangiocyte differentiation medium. Yellow arrow: cells which expressed CK19 protein. (H) 
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Similar to hepatocytes in liver tissue (upper panel; HNF4ɑ: yellow), the differentiated cells after 
culture in hepatocyte differentiation medium showed larger nuclei (lower panel), compared to 
undifferentiated cells (middle panel). Yellow scale: 50 µm. Yellow arrow: cell which showed large 
nucleus.  
 
LRCs Respond to Liver Injury and Induce Lgr5 Expression In Vivo 
To investigate whether LRCs can respond to liver injury, we induced an acute injury by 
a single treatment of CCl4 in mice after 3-7 months of chasing. Compared to LRCs in the 
homeostatic liver, we observed that LRCs from the injured liver shifted towards lower 
expression of GFP (n = 5; Figure 6A and Supplementary Figure 13A). This result indicated 
that CCl4-treatment triggered the proliferation of LRCs, therefore diluting the GFP levels 
per cell. To better clarify this effect, we further defined the LRCs population into high-GFP-
LRCs (e.g. GFP expression level > 1× 104, GFP-bright) and low-GFP-LRCs (GFP 
expression level < 1× 104) populations. We found that there were 41.8 ± 3.4% of high-
GFP-LRCs and 58.2 ± 3.4% low-GFP-LRCs in homeostasis (mean ± SEM, n = 5). At day 3 
of post-CCl4 injection, the bright GFP population was dramatically decreased from 41.8 ± 
3.4% to 23.8 ± 3.0% of the total label retaining population (n = 5) (Figure 6B-D, and 
Supplementary Figure 13B). Similar results were observed, when defining the high-GFP-
LRC population based on different levels of GFP expression (Supplementary Figure 13C-
D). This indicated that a large proportion of the quiescent LRCs entered the cell cycle in 
response to injury, although the percentage of LRCs within the entire cell population did 
not significantly change (Supplementary Figure 9H).  
We further confirmed the activation of LRCs in the injured liver by visualization of the 
expression of the proliferation marker KI67 by immunofluorescence (Figure 6E). In 
contrast, LRCs in homeostatic liver did not express KI67 (Supplementary Figure 14A). 
qRT-PCR also confirmed the upregulation of Ki67 expression in LRCs isolated from the 
injured liver; whereas it is not expressed in LRCs isolated from the homeostatic liver 
(Figure 6F). 
Furthermore, LRCs from injured liver can form organoids, with similar efficiency as 
normal liver derived LRCs (Figure 6G, and Supplementary Figure 9E and G). However, 
LRCs from injured liver formed significantly larger organoids, which also grew faster, as 
shown by the organoid diameters measured at day 7 (Normal vs Injury = 101 ± 21 µm vs. 
187 ± 35 µm). The same pattern was also observed on day 11 and 15 (Figure 6G-H). 
These observations were also found in the bile duct derived LRCs from homeostatic and 
injured livers (Figure 6I-L, and Supplementary Figure 9F and G).  
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Most interestingly, we detected Lgr5 expression by qRT-PCR in LRCs directly isolated 
from the injured liver; whereas it was not expressed in LRCs isolated from the homeostatic 
liver or non-LRCs from both types of livers (Figure 7A). This is consistent with our 
observation that Lgr5 expression emerges during organoid culture, but is absent in the 
initial isolated LRCs derived from the healthy liver (Figure 4G). In addition, we found that 
injury triggered the upregulation of CD44 and SOX9 in LRCs, as demonstrated by qRT-
PCR of isolated single cells (Figure 7A) and immunofluorescent staining of in situ protein 
expression (Figure 7B-C). CD44 and SOX9 expression were retained in LRCs cultured 
organoids (Figure 7D-E). Isolated LRCs from injured compared to homeostatic liver also 
showed a trend of upregulation of other progenitor/stem cell markers, including Sox17, 
Cd133, Oct4, Nanog and Sox2 (Figure 7A). In contrast, LRCs expressed relatively lower 
levels of maturation markers including Tbx3, Cyp3a11, Pparg and Alb, compared to non-
LRCs (Figure 7A). Taken together, these results indicated that quiescent LRCs rapidly 
respond to liver injury and give rise to Lgr5-expressing cells, as well as other potential 
progenitor/stem cells.  
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Figure 6. LRCs responded to liver injury. (A) Representative FACS results showing that the LRCs 
shifted towards a relatively lower expression of GFP, upon 3 days of CCl4 injury. (B-C) 
Representative flow cytometry pictures showing that liver LRCs responded to injury indicated by 
the decreased percentage of GFPbright-LRC population. FSC: forward scatter. (D) Absolute 
numbers of all five paired samples showing that liver LRCs responded to injury indicated by the 
decreased percentage of GFPbright-LRC population (*P < .05; n = 5). (E) Representative confocal 
images showing the expression of proliferation marker KI67 in injured liver. Yellow arrow: LRCs 
with KI67 expression in injured liver. KI67: red; DAPI: blue; LRCs: Green. (F) Gene expression 
quantified by qRT-PCR showed that injured liver LRCs expressed higher levels of proliferation 
marker Ki67, compared to homeostatic liver derived LRCs (*P < .05; n = 3). (G) Organoids cultured 
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from LRCs derived from healthy or CCl4 treated mice liver. (H) Injury stimulated the growth of 
LRCs derived organoids. The differences of organoid diameters were measured at day 7 (**P 
< .01), day 11 (*P < .05) and day 15 of culture. Cells analyzed here were derived from three groups 
of mice. (I) The organoid initiation efficiency of LRCs and non-LRCs from injured liver, isolated 
from entire liver (n = 3, *P < .05). (J) The organoid initiation efficiency of LRCs and non-LRCs from 
injured liver, isolated from bile duct. (K) Representative pictures of organoids cultured from Duct-
LRCs derived from healthy or CCl4 treated mice. (L) Injury stimulated the growth of Duct-LRCs 
derived organoids. The differences of organoid diameters were measured at post day 7 and day 11 
of culture (*P < .05). Cells analyzed here were derived from three groups of mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. LRCs expressed low levels of hepatocyte markers, but high level of progenitor markers. 
(A) For freshly isolated LRCs and non-LRCs derived from normal and injured mice livers (paired 
mice), gene expression quantified by qRT-PCR showed that LRCs expressed relatively higher 
levels of progenitor markers and lower levels of hepatic/mature markers, compared to non-
LRCs.(*P < .05; **P < .01; n = 5). Values were normalized against Gapdh expression. (B-C) 
Representative confocal images showing the expression of CD44 (B) and SOX9 (C) in LRCs, upon 
liver injury. CD44: yellow; DAPI: blue; SOX9: red; LRCs: green. Yellow arrow: LRCs expressed 
CD44/SOX9 protein. (D-E) Injured liver derived LRCs initiated organoids which expressed CD44 
(D) and SOX9 (E). DAPI: Blue; CD44: yellow; SOX9: red. Yellow arrow: cells expressed 
CD44/SOX9 protein 
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Discussion: 
This study has demonstrated that slow-cycling/quiescent cells (LRCs) identified by label 
retaining technique are bona fide stem cells in the mouse liver. In fact, LGR5 proliferative 
stem cells are absent in the homeostatic liver but only activated by liver injury, which is 
dispensable for injury recovery. More interestingly, we revealed that quiescent LRCs can 
be activated by liver injury and give rise to LGR5 proliferative stem cells. 
Unlike in the liver, LGR5 stem cells in intestine, colon and skin are present at 
homeostatic status and participate in tissue renewal by compensating the loss of 
differentiated cells.2, 24, 25 Despite their essential role in homeostatic maintenance in these 
tissues, loss of LGR5 stem cells in the intestine can be compensated by 
transdifferentiation from the quiescent stem cell pool,8, 26 or through plasticity of their 
enterocyte-lineage daughters.27 This is in line with our findings that liver LGR5 stem cells 
are dispensable for organoid initiation and expansion ex vivo, and are limited in tissue 
repair in vivo. 
Although slow-cycling cells have been identified in the mouse liver,23, 28 their function 
however has never been studied mainly because of technical limitations. Classically, 
nucleotide analogs that incorporate into genomic DNA have been widely used to identify 
slow-cycling cells including in liver, intestine, esophagus and stomach.23, 29, 30 However, 
these compounds, such as BrdU, have major drawbacks: 1) It preferentially labels 
proliferating cells; 2) in vivo labeled cells are unable to be isolated for further functional 
investigation; 3) in turn trigger cell proliferation from quiescent stage.19, 26 The unique 
advantage of this study is to use transgenic mice that can conditionally and efficiently label 
cells by a nuclear localized GFP reporter. This model allows identification of bona fide 
quiescent cells with a labeling efficiency higher than 80% and over 450 days of label 
fading (Figure 4, and Supplementary Figure 6). Most importantly, living LRCs can be 
isolated based on GFP expression and subjected to functional experimentation. 
Here we reveal that similar to LGR5 cells, LRCs are localized around/within the bile duct, 
a well-accepted liver stem cell niche,31 and consistent with streaming liver theory.21, 26 
Isolated LRCs express relatively low levels of hepatic markers, including Hnf4a, Tbx3, 
Pparg, Cyp3a11, Fah and Albumin. Functionally, isolated LRCs are able to initiate 
organoids, which can be expanded and passaged for months, confirming their stem cell 
property. By switching expansion medium into lineage differentiation media, these 
organoids switch into hepatocyte or cholangiocyte fate. This is consistent with a previous 
study of lineage differentiation of human liver organoids.32  
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Impressively, the liver harbors a small proportion of extremely quiescent cells that are 
capable of retaining the GFP label over one year. These LRCs have strong stem cell 
characteristics, showing the capability of organoid initiation and enriched expression of 
quiescent stem cell markers, including Mex3a, Bmi1 and Lrig1.33  
LRCs do not express Lgr5 at homeostatic status, but are activated by injury and give 
birth to Lgr5 proliferative stem cells in vivo. This is similar to the intestine that Bmi1-
marked quiescent stem cells can compensate for the loss of LGR5 proliferative stem 
cells.8 it is however very different from another scenario in the intestine that LGR5 stem 
cells can be generated through dedifferentiation of their enterocyte-lineage daughters.27 In 
the liver, LRCs are present in homeostasis and LGR5 cells only emerge upon injury, which 
preclude the possibility of LRCs as daughter cells of LGR5 stem cells. In response to injury, 
LRCs also give birth to other progenitor/stem cell populations, including SOX9 and CD44 
cells. SOX9-expressing cells are enriched both in the LRCs from homeostatic (Figure 4F) 
and injured liver (Figure 7A) and have been demonstrated to be able to replace the bulk of 
the hepatocyte mass in several settings.22 CD44-expressing cells are not enriched in LRCs 
or non-LRCs from homeostatic liver (Figure 4F), but specifically emerged upon injury 
within the LRC population (Figure 7A). CD44-expressing cells are considered as an 
important mesenchymal/neural stem cells marker or cancer stem cell marker for several 
types of cancers34-38. Our results indicate a potential role of CD44 in the liver stem cell 
compartment, deserving further investigation. Here, we provide evidence that multiple 
progenitor/stem cell populations dynamically respond and participate in injury recovery of 
the liver and LRCs likely serve as an early-stage stem cell population.  
In summary, our study functionally proved that quiescent/slow-cycling cells in the mouse 
liver are stem cells. They respond to tissue injury and can give rise to the Lgr5 proliferative 
stem cells. It will be of particular interest to also study these stem cell populations in 
human liver. However, innovative techniques need to be developed for identification of 
quiescent/slow-cycling cells in human, which will enable functional studies of the identified 
cells.  
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Supplementary Materials and Methods: 
Bile Duct Derived Organoid Culture  
    Biliary ducts were isolated from mouse liver using digestion solution I: 125 µg/ml of 
Collagenase type XI (Sigma-Aldrich), 125 µg/ml of Dispase (Gibco), 100 µg/1ml of Dnase-
1 (Sigma-Aldrich), 1% FBS in DMEM medium (Lonza) (37°C, 30min). Isolated bile ducts 
were mixed with matrigel (BD Bioscience) and seeded on 24/48 well plate, as described 
previously.1 Medium was added after the matrigel formed a solid gel. Organoid culture 
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medium was based on advanced DMEM/F12 (Invitrogen), which is supplemented with 2% 
(vol/vol) of B27 and 1% (vol/vol) of N2 (Invitrogen), 1.25 μM N-acetylcysteine (Sigma-
Aldrich, antioxidant agent), 10 nM gastrin (Sigma-Aldrich), 50 ng/ml EGF (Peprotech, 
epidermal growth factor), 10% (vol/vol) of R-spondin-1 (conditioned medium produced by 
293T-H-RspoI-Fc cell line, WNT/β catenin signaling pathway activator), 100 ng/ml FGF10 
(Peprotech, fibroblast growth factor 10), 10 mM nicotinamide (Sigma-Aldrich) and 50 ng/ml 
HGF (Peprotech, hepatocyte growth factor). For the first 4 days, the organoids were also 
supplemented with 10% (vol/vol) of Noggin (conditioned medium produced by 293T-HA-
Noggin cell line, bone morphogenic protein ligands antagonist) and 30% (vol/vol) of Wnt3a 
(conditioned medium produced by L-Wnt3a cell line, WNT/β-catenin signaling pathway 
activator). Medium was refreshed every 2-3 days and passage was performed in 1:2-1:4 
split ratio once per week. 
 
Single Cell Derived Organoid Culture 
    Digestion solution II (500µg/ml of collagenase type XI, 200µg/ml of Dnase-1, 1% FBS in 
DMEM medium) was used to digest liver tissues into single cell suspension (37°C, 30min). 
A FACSAriaTM II cell sorter (BD Biosciences) was used to isolate the target cell population. 
Propidium iodide (PI) staining was performed to exclude dead cells and CD45 staining was 
adopted for excluding leucocytes. Single-sorted LGR5-GFP+ cells, LGR5-GFP- cells, LRCs 
and non-LRCs were mixed with matrigel separately and seeded for organoid initiation. 
Cells were cultured in organoid culture medium mentioned above. For the first 8-12 days, 
the organoids were supplemented with 10 μM Y-27632 (Sigma-Aldrich, RHO/ROCK 
pathway inhibitor), Noggin and Wnt3a conditioned medium. Medium was refreshed every 
2-4 days and passage was performed in split ratios of 1:2-1:4 weekly for at least 8 months.  
 
Hepatocyte Differentiation 
    To enhance hepatocyte fate, LRC-derived organoids were first seeded and maintained 
in organoid culture medium as described above for 2-4 days. Then, the medium was 
changed to organoid differentiation medium. Organoid differentiation medium was based 
on organoid culture medium, which no longer contained R-spondin 1, HGF and 
nicotinamide but contained 50 nM A8301 (Tocris Bioscience, TGF-βRI inhibitor) and 10 nM 
DAPT (Sigma-Aldrich, Notch inhibitor). For the last 3  days of the differentiation, cultures 
were also supplemented with dexamethasone (30 μM, Sigma-Aldrich, Glucocorticoid 
pathway activator). Medium was changed every other day for a period of 9 to 18 days.2  
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Cholangiocyte Differentiation 
    To enhance cholangiocyte fate, LRC-derived organoids were first seeded and 
maintained in organoid culture medium as described above for 2-4 days. Then, the 
medium was changed to cholangiocyte directed differentiation medium (phase 1) for 4 
days. Phase 1 medium was based on advanced DMEM/F12, which was supplemented 
with B27, 50 ng/ml FGF10, 50ng/ml activin-A (Sigma-Aldrich, TGF-β family member) and 3 
μM RA (Sigma-Aldrich, all−trans−Retinoic acid). Next, medium was changed to 
cholangiocyte directed differentiation medium (phase 2), Phase 2 medium was also based 
on advanced DMEM/F12, which was supplemented with 10 mM nicotinamide, 17 mM 
sodium bicarbonate (Sigma Aldrich), 0.2 mM 2-Phospho-L-ascorbic acid trisodium salt 
(Sigma-Aldrich), 6.3 mM sodium pyruvate (Invitrogen, carbon source), 14 mM glucose 
(Sigma-Aldrich), ITS+ premix (BD Biosciences, contains insulin, human transferrin, and 
selenous acid mainly), 0.1 uM dexamethasone, 2 mM Glutamax (Invitrogen) and 20 ng/ml 
EGF. Medium was changed every other day for two weeks.3  
 
FACS Analysis 
    For FACS analysis, single cells derived from liver, intestine and organoids were 
suspended in DMEM plus 2% FBS. Cell suspensions were analyzed using a BD 
FACSCalibur or BD FACSAriaTM II. 
 
Histology, Immunohistochemistry and Immunofluorescence 
    Liver or intestine was fixed in 4% paraformaldehyde (PFA) overnight at 4°C. For 
immunofluorescence, samples were further dehydrated with 30% sucrose (Sigma-Aldrich) 
at 4°C overnight, embedded in OCT gel, stored at -80°C and then sectioned at 8 μm for 
further analysis. Images were acquired with a Zeiss LSM510META confocal microscope. 
For histology and immunohistochemistry, materials were dehydrated with 70% ethanol, 
embedded with paraffin, sectioned at 4 μm for staining. Images were acquired with a Zeiss 
Axioskop 20 microscope. All antibodies are listed in Supplementary Table 1. 
 
qRT–PCR  
For organoids, Machery-NucleoSpin RNA II kit (Bioké) was used to extract RNA; for 
freshly sorted cells, RNeasy Micro Kit (QIAGEN) was used to isolate RNA. After 
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quantification with Nanodrop ND-1000 (Wilmington), RNA was converted to cDNA using a 
cDNA Synthesis kit (TAKARA BIO INC.). Real-time PCR reactions were performed with 
SYBRGreen-based real-time PCR (Applied Biosystems®) and amplified in a thermal cycler 
(GeneAmp PCR System 9700) according to the manufacturer’s instructions. 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) gene was used as reference. All 
primers are listed in Supplementary Table 2. 
 
Statistical Analysis. 
    Prism software (GraphPad Software) was used for all statistical analysis. For statistical 
significance of the differences between the means of two groups, we used Mann-Whitney 
U-test. Differences were considered significant at a P value less than 0.05. 
 
 
Supplementary References 
1. Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced 
by Wnt-driven regeneration. Nature 2013;494:247-50. 
2. Jaks V, Kasper M, Toftgard R. The hair follicle-a stem cell zoo. Exp Cell Res 
2010;316:1422-8. 
3. Sampaziotis F, Cardoso de Brito M, Madrigal P, et al. Cholangiocytes derived from human 
induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol 
2015;33:845-52. 
Author names in bold designate shared co-first authorship. 
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Supplementary Figure 1. LGR5 stem cells were absent in the homeostatic liver over the life span 
of a mouse, but emerged upon injury. (A) Representative flow cytometry plots for LGR5-GFP+ cells 
at different age of mice (in week, n = 3). (B) Representative flow cytometry plots for LGR5-GFP+ 
cells in injured livers by single or repeated CCl4 injections. (C) Representative liver and H&E 
staining showing normal (left panel), injury by single CCl4 (middle panel) and injury by multiple CCl4 
injections (right panel). Original magnifications were ×40. (D) Absolute percentages for LGR5-
GFP+ cells in CCl4 injured livers. (E-F) Serial images showing the outgrowth of a single sorted 
LGR5-GFP+ cell (E) and two sorted LGR5-GFP- cells (F). Original magnifications were ×100. (G) 
The organoid initiation efficiency of LGR5-GFP+ and LGR5-GFP- from chronic injured livers with 4 
months of repeated CCl4 induction (n = 2).  
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Supplementary Figure 2. The immunohistochemistry staining of LGR5+ cells which expressed 
GFP. (A) Representative immunohistochemistry pictures of negative control for anti-GFP staining. 
Without adding primary antibody: left panel; the negative sample which did not express GFP: right 
panel. (B-C) Representative immunohistochemistry pictures of LGR5-GFP+ cells (presenting 
sample: long term CCl4 induced injured liver), which was stained with anti-GFP antibody. Red 
arrow: LGR5+ cells. Nuclear: blue; GFP: brown.   
 
 
49 | P a g e  
 
  
50 | P a g e  
 
Supplementary Figure 3. LGR5 stem cells in recovery of liver injury. (A) A schematic illustration 
of Lgr5-CreERT2/Rosa26-YFP transgenic mice used. (B) Schemes showing the lineage tracing 
strategies. (C) Representative flow cytometry plots for daughter cells (YFP) derived from LGR5+ 
cells in the liver and intestine with Lgr5-CreERT2/Rosa26-YFP transgenic mice without or with 
CCl4 induced injury (number showed in percentage). SSC: side scatter. (D-E) Percentages of the 
daughter cells (YFP) derived from LGR5 cell with single CCl4 injury in liver (D) and intestine (E), 
post day 5 and day 25. (F) A schematic illustration of the Lgr5-CreERT2/Rosa26-mTmG transgenic 
mice used. (G) Representative confocal images showing LGR5 derived offspring cells in Lgr5-
CreERT2/Rosa26-mTmG mice after acute liver injury, at day 5 and 25 of post TAM induction. CTR: 
no TAM induced control; DAPI: blue; LGR5 derived offspring: green; Normal cells: red; Yellow 
arrow: daughter cells derived from liver LGR5+ cells.  
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Supplementary Figure 4. Immunohistochemistry staining of LGR5+ cells and their offspring cells 
which expressed membrane-targeted green fluorescent protein (mG). (A) Representative 
immunohistochemistry picture of negative control for anti-GFP staining. Without adding primary 
antibody: left panel; The negative sample which did not express GFP: right panel. (B) 
Representative immunohistochemistry pictures of intestinal LGR5-mG cells, which was stained 
with anti-GFP antibody. The negative sample which did not express GFP: left panel. (C) 
Representative immunohistochemistry pictures of LGR5-mG cells (presenting sample: acute CCl4 
induced liver injury, post TAM day25), which was stained with anti-GFP antibody. Red arrow: 
LGR5+ and daughter cells.  
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Supplementary Figure 5. DT depletion in organoids. (A) The FACS testing strategy of LGR5-
GFP+ cells from organoids. (B) Representative organoid pictures (upper panel; Original 
magnifications were ×40) and flow cytometry plots (lower panel) showing the organoids were 
treated with different concentrations of DT. Concentrations arranged from 0-100 ng/ml (n = 3). (C) 
Representative organoid pictures showing the wild type mice liver derived organoids treated with 
different concentrations of DT. Concentrations arranged from 0-100 ng/ml (n = 3). (D) The 
organoid initiation efficiency of organoids derived from Lgr5-DTR-GFP and wild type mice liver, 
under the treatment of different concentrations of DT. DTR: Lgr5-DTR-GFP mice liver derived 
organoids; WT: wild type mice liver derived organoid. Upper panel: the raw initiated organoid 
numbers. Lower panel: the relative organoid initiation efficiencies which normalized to the 
corresponding control (without DT treatment). NS: not significant.   
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Supplementary Figure 6. The induction efficiency of three rtTA/GFP transgenic mice. (A) Diagram 
representing of rtTA/GFP transgenic mice. (B) Transgenic rtTA/GFP mice were fed with dox water 
to induce H2BGFP expression for one week, then 7 month of chasing as indicated in the scheme. 
(C) Representative confocal microscopic pictures showing before/after dox induction in the liver of 
three rtTA/GFP transgenic mouse models. PV: portal vein. CV: central vein. Red arrow: bile duct 
structure. CTR: control. (D) Representative flow cytometry plots showing induction condition. SSC: 
side scatter. CTR: control. DOX: doxycycline induction (n = 2).  
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Supplementary Figure 7. Liver cells gradually lost GFP label during long-term fading period. (A-B) 
Representative flow cytometry plots (A) and absolute percentages of GFP+ (B) showing liver cells 
slowly lost GFP label during long-term chasing period. SSC-A: side scatter area (Month 0: n = 3; 
Month 1: n = 2; Month 3: n = 2; Month 4: n = 2; Month 5: n = 4; Month 7: n = 4).  
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Supplementary Figure 8. LRCs did not express hepatocyte marker HNF4ɑ. Representative 
confocal images for hepatocyte marker HNF4ɑ expression in LRCs, month 3 LRCs (upper panel), 
month 6 LRCs (lower panel). HNF4ɑ: yellow; DAPI: blue; LRCs: Green; PV: portal vein. CV: central 
vein.   
 
 
59 | P a g e  
 
  
60 | P a g e  
 
Supplementary Figure 9. Organoid formation of LRCs derived from homeostatic and injured 
mouse livers. (A-B) The organoid initiation efficiency of LRCs and non-LRCs from homeostatic liver 
(post dox induction month 3-7), isolated from the entire liver (A) (n = 5) or from bile duct (B) (n = 3). 
(C-D) The organoid initiation efficiency of LRCs and non-LRCs from homeostatic liver (post dox 
induction month 14-15), isolated from the entire liver (C) (n = 4) from bile duct (D) (n = 4). (E-F) 
The organoid initiation efficiency of LRCs and non-LRCs from injured liver, isolated from the entire 
liver (E) (n = 3) or from bile duct (F) (n = 3). (G) Comparison of organoid initiation efficiency 
between LRCs from healthy liver (month 3-7) and injured liver. E: entire liver derived LRCs; D: bile 
duct derived LRCs. (H) The percentage of LRCs within the entire cell population from both 
homeostatic and injured liver (NS: not significant).  
 
 
61 | P a g e  
 
 
Supplementary Figure 10. The panel of progenitor cell markers which did not show specific 
enrichment. Both LRCs or non-LRCs (freshly isolated, from month 3-15) did not show enrichment 
for those markers, as quantified by qRT-PCR. Values were normalized against Gapdh expression 
(n = 6). 
 
 
 
 
 
 
 
 
Supplementary Figure 11. LRCs derived organoids lost the expression of progenitor markers 
upon hepatocyte differentiation. (A-B) LRCs derived organoids lost the expression of CD44 (A) and 
SOX9 (B) upon differentiation. C: negative control; D: CD44/SOX9 expression upon differentiation.  
62 | P a g e  
 
 
Supplementary Figure 12. LRCs could differentiate towards hepatocyte and cholangiocyte 
lineages. (A-B) Gene expression of LRCs derived organoids for progenitor (A), hepatocyte and 
maturation markers (B), compared between expansion and cholangiocyte directed differentiation 
phase. E: expansion. CD: cholangiocyte directed differentiation. Values were normalized against 
Gapdh expression (*P < .05; **P < .01; n = 4).   
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Supplementary Figure 13. LRCs responded to injury. (A) All of the five paired mice (paired mice: 
start/stop the dox induction in the same day; sacrifice within 1 day) showed that the LRCs shifted 
towards a relatively lower expression of GFP, upon 3 days of CCl4 injury. (B-D) Representative 
FACS graphs (for No.1 samples, Left three figures) and absolute percentages (for all five pairs, 
right two figures) showing that the bright GFP population was dramatically decreased after three 
days of CCl4 injury (*P < .05; n = 5). N: normal; I: injury: M: merged FACS figures from normal and 
injury.   
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Supplementary Figure 14. LRCs in healthy liver did not express proliferation marker KI67. (A) 
LRCs in healthy liver did not express KI67. DAPI: Blue; LRCs: Green; KI67: Red. Yellow arrow: 
one non-LRC expressed KI67 protein. (B) Positive control for anti-KI67 staining, indicating the 
intestinal cells with higher index of proliferation.   
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Supplementary Table 1.  
Antibody Antibody clone/ reference Raised Origin 
CD45 56-0451-82 Mouse eBioscience 
Albumin sc46291 Goat STCruz 
GFP A-11122 Rabbit Invitrogen/Life 
Technologies 
KI67 ab15580 Rabbit Abcam 
HNF4ɑ sc-8987 X Rabbit STCruz 
CK19 ab52625 Rabbit Abcam 
CD44 ab157107 Rabbit Abcam 
SOX9 AB5535 Rabbit Millipore 
Alexa Fluor® 488 
AffiniPure Donkey Anti-
Goat IgG (H+L) 
705-545-147 Donkey Bio-Connect 
 
Donkey anti-Rabbit IgG 
(H+L) Secondary Antibody, 
Alexa Fluor® 594 
conjugate 
A-21207 Donkey Thermo fisher 
Donkey anti-Goat IgG 
(H+L) Cross-Adsorbed 
Secondary Antibody, 
Alexa Fluor 594 
A-11058 Donkey Thermofischer 
Donkey anti-Goat IgG 
(H+L) Secondary Antibody, 
Alexa Fluor® 647 
conjugate 
A-21447 Donkey Life Technologies 
Supplementary Table 2 
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Gene name Gene 
Symbo 
Sequence 
Leucine-rich repeat-containing G-protein 
coupled receptor 5 
Lgr5 fw CTG ACT TTG AAT GGT GCC TCG 
re ATG TCC ACT ACC GCG ATT AC 
Albumin Alb fw TCC TGA TTG CCT TTT CCC AGT ATC T 
re GCC AGT TCA CCA TAG TTT TCA CGG A 
Hepatocyte nuclear factor 4ɑ Hnf4ɑ fw CAG ACG TCC TCC TTT TCT TGT GAT 
re TGT TTG GTG TGA AGG TCA TGA TTA 
Bone morphogenetic protein 2 Bmp2 fw TGA GGA TTA GCA GGT CTT TG 
re CAC AAC CAT GTC CTG ATA AT 
Peroxisome proliferator-activated receptor 
gamma 
Pparg fw GCC CTT TGG TGA CTT TAT GGA 
re GCA GCA GGT TGT CTT GGA TG 
T-box transcription factor Tbx3 fw CCA CCC GTT CCT CAA TTT GAA CAG 
re CGG AAG CCA TTG ATG GTA AAG CTG 
Glucose-6-phosphatase, catalytic subunit G6pc fw TCC CCA GAA TTC TCC ACT TG 
re AAC ATC GGA GTG ACC TTT GG 
Fumarylacetoacetase Fah fw CAT GGG TCT GGG TCA AGC 
re AGG TCC CCA GGT CTC AGG 
Cytochrome P450, family 3, subfamily a, 
polypeptide 11 
Cyp3a11 fw GAC AAA CAA GCA GGG ATG GAC 
re CCA AGC TGA TTG CTA GGA GCA 
Antigen KI-67 ki67 fw CTG CCT GCG AAG AGA GCA TC 
re AGC TCC ACT TCG CCT TTT GG 
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Antigen Cd44 Cd44 fw CGT CCA ACA CCT CCC ACT AT 
re AGC CGC TGC TGA CAT CGT 
Transcription factor SOX-9 Sox9 fw CGA CTA CGC TGA CCA TCA GA 
re GAC TGG TTG TTC CCA GTG CT 
SRY (sex determining region Y)-box 17 Sox17 fw GGC GCA GCA GAA TCC AGA 
re CCA CGA CTT GCC CAG CAT 
Antigen Cd133 Cd133 fw TCT GTT CAG CAT TTC CTC AC 
re TCA GTA TCG AGA CGG GTC 
Transcription factor Nanog Nanog fw AGG GTC TGC TAC TGA GAT GCT CTG 
re CAA CCA CTG GTT TTT CTG CCA CCG 
Octamer-binding transcription factor 4 Oct4 fw CTG TAG GGA GGG CTT CGG GCA CTT 
re CTG AGG GCC AGG CAG GAG CAC GAG 
SRY (sex determining region Y)-box 2 Sox2 fw GGC AGC TAC AGC ATG ATG CAG GAG C 
re CTG GTC ATG GAG TTG TAC TGC AGG 
Cytokeratin-19 Ck19 fw GTG AAG ATC CGC GAC TGG T 
re AGG CGA GCA TTG TC AAT CTG 
Cytokeratin 7 Ck7 
 
fw ATC CGC GAG ATC ACC ATC 
re ATG TGT CTG AGA TCT GCG ACT 
Leucine-rich repeats and immunoglobulin-like 
domains protein 1 
Lrig1 fw AAG GGA ACT CAA CTT GGC GAG 
re ACG TGA GGC CTT CAA TCA GC 
Telomerase reverse transcriptase Tert fw GCA GGT GAA CAG CCT CCA GAC AG 
re TCC TAA CAC GCT GGT CAA AGG GAA GC 
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Oligomeric mucus/gel-forming Muc5ac fw GGA CCA AGT GGT TTG ACA CTG AC 
re CCT CAT AGT TGA GGC ACA TCC CAG 
Mucin 1, cell surface associated Muc1 
 
fw CCC CAG TTG TCT GTT GGG GTC 
re GGA TTC TAC CAC CAC GGA GCC 
Mex-3 RNA Binding Family Member A Mex3a 
 
fw ACA CCA CGG AGT GCG TTC 
re GTT GGT TTT GGC CCT CAG A 
Polycomb complex protein BMI-1 Bmi1 fw TTC ATT GAT GCC ACA ACC AT 
re CAG CAT CAG CAG AAG GAT GA 
Homeodomain-only protein Hopx fw CAT CCT TAG TCA GAC GCG CA 
re AGG CAA GCC TTC TGA CCG C 
Olfactomedin 4 Olfm4 fw TGG CCC TTG GAA GCT GTA GT 
re ACC TCC TTG GCC ATA GCG AA 
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CHAPTER 3 
 
Modeling liver cancer and therapy responsiveness using 
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Abstract 
The current understanding of cancer biology and the availability of effective treatments for 
cancer remain far from satisfactory. In order to facilitate cancer research, easy and robust 
model systems are required that resemble the architecture and physiology of the tumors in 
patients. Cancer research has mainly been based on the use of immortalized cancer cell 
lines that have been propagated in 2D culture for decades, which deviate in many aspects 
from the original primary tumors. The recent development of the organoid technology 
allowing generation of organ-buds in 3D culture from adult stem cells has endowed the 
possibility of establishing stable culture from primary tumors. Although culturing organoids 
from liver tumors is thought to be difficult, we now convincingly demonstrate the 
establishment of organoids from mouse primary liver tumors. We have succeeded in 
establishing 90 lines from 128 tumors. These organoids can be grown in long-term 
cultures and expand in vitro. A subset of these liver cancer organoids have the potential to 
initiate tumors in immunodeficient mice upon (serial) transplantation, confirming their 
malignant and cancer stem cell-like properties. Interestingly, a single organoid derived 
from a single cancer cell is able to initiate tumor in mice, indicating the enrichment of 
tumor-initiating cells in the organoids. Furthermore, these organoids recapitulate, to some 
extent, the heterogeneity of liver cancer as seen in patients, with respect to phenotype, 
cancer cell composition and treatment response. These model systems provide new 
research opportunities to advance knowledge on liver cancer (stem cell) biology, drug 
development and personalized medicine. 
Keywords: Tumor organoid, Liver tumor, Anti-cancer research  
72 | P a g e  
 
1. Introduction 
Liver cancer is one of the most common cause of cancer-related death worldwide with 
limited treatment options available [1]. Better understanding of the biology of liver cancer is 
urgently needed to facilitate the development of new therapies. However, this in turn 
heavily relies on the availability of easy and robust model systems that resemble the 
architecture and physiology of the tumors in patients. So far, the cancer research society 
has mainly used immortalized cancer cell lines that have been propagated in 2D culture for 
decades. Obviously, these cell lines behave very different from the original tumor in many 
aspects [2]. Primary cell culture of liver cancer cells from either human or mouse has 
proven to be very difficult [3]. Thus, innovative approaches enabling in vitro propagation of 
primary liver cancer cells that maximize the modeling capacity of the patient disease and 
treatment response will be of particular importance. 
The recent development of the organoid technology has driven the stem cell research 
field moving forward. Organoids are initiated in vitro from one or a few adult stem cells of a 
particular tissue/organ and self-organize into 3D structures [4]. They recapitulate the tissue 
architecture and lineage hierarchy, allow self-renewal and expansion of the stem cell 
population and empower different types of experimental manipulation [5]. Many types of 
cancers are believed to harbor a subset of cells, often termed as tumor-initiating cells (TIC). 
Thus, it is conceivable that organoids could be cultured from tumor tissues, if sophisticated 
3D cell culture techniques/conditions are employed. Indeed, tumor organoid models have 
been successfully established from primary colorectal [6], pancreas [7] and prostate 
cancer tissues [8]. This technology is now used to explore many aspects of cancer 
research, including studying oncogenic transformation, cancer stem cells, drug 
development and personalized treatment [9, 10]. Our study presents the successful 
establishment of malignant organoid models from mouse primary liver tumors and 
demonstrates their applications in liver cancer research.  
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2. Materials and Methods: 
2.1. Primary liver tumor model 
    C57Bl6 (B6), C3H and CD1 were purchased from Charles River. And then C57Bl6 (B6) 
mice were further bred with C3H or CD1 into B6/C3H and B6/CD1 separately. B6, B6/C3H 
and B6/CD1 mice (3-4 weeks) were administrated weekly with Diethylnitrosamine (DEN) 
by intraperitoneal injection (i.p., 100 mg/kg) for 6-17 weeks. Mice were sacrificed 3-16 
months after the last DEN injection and livers were collected for further experiments. All 
animal experiments were approved by the Committee on the Ethics of Animal Experiments 
of the Erasmus Medical Center. 
 
2.2. Immunohistochemistry and Immunofluorescence of tissues 
    Liver or liver tumor was fixed in 4% paraformaldehyde (4°C, overnight). For 
immunofluorescence, samples were further dehydrated with 30% sucrose solution 
overnight, stored at -80°C and then sectioned at 8 μm for further analysis. For 
immunohistochemistry and H&E staining, materials were embedded in paraffin according 
to standard procedures and sectioned at 4 μm for further staining. All antibodies are listed 
in Supplementary Table 4. 
 
2.3. Immunohistochemistry and Immunofluorescence of organoids 
    For immunofluorescence, cold advanced DMEM/F12 medium was used to collect the 
organoids. Organoids were fixed in 4% paraformaldehyde for 10 min, and centrifuged onto 
the slice for staining (Cytospin, 1000rpm×3min). For H&E staining and 
immunohistochemistry, the organoids including the matrigel were directly fixed with 4% 
paraformaldehyde for 30 min in room temperature, embedded in 1% agarose, further 
embedded in paraffin, and sectioned at 4 μm for further analysis. 
 
2.4. Tumor organoid culture  
    Single cells were isolated from mouse liver tumor tissues using a digestion solution: 
Collagenase type XI (0.5 mg/ml, Sigma-Aldrich), Dispase (0.2 mg/ml, Gibco), 1% FBS in 
DMEM medium (Lonza) (37°C, 30min), then centrifuged (600rpm, 10min) to collect the cell 
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pellets. Cells were directly mixed with matrigel (BD Bioscience), seeded on 24/48 well 
plates and kept at 37°C for at least 30 min. After the matrigel formed a solid gel, medium 
was slowly added. Organoid culture medium was based on advanced DMEM/F12 
(Invitrogen), which is supplemented with B27 (2% vol/vol, Invitrogen) and N2 (1% vol/vol, 
Invitrogen), N-acetylcysteine (1.25 μM, Sigma-Aldrich), gastrin (10 nM, Sigma-Aldrich), 
EGF (50 ng/ml, Peprotech), R-spondin 1 (10% vol/vol, conditioned medium produced by 
293T-H-RspoI-Fc cell line), FGF10 (100 ng/ml, Peprotech), nicotinamide (10 mM, Sigma-
Aldrich) and HGF (50 ng/ml, Peprotech). For the initial 3 days, the organoids also need to 
be supplemented with Noggin (10% vol/vol, conditioned medium produced by 293T-HA-
Noggin cell line) and Wnt3a (30% vol/vol, conditioned medium produced by L-Wnt3a cell 
line) [4]. Medium was refreshed every 2-3 days and organoids were passaged in 1:2-1:10 
split ratio once per week, or according to the growth of the organoids. 
 
2.5. Organoid allografting 
    Cold advanced DMEM/F12 medium was used to collect the organoids. After 
centrifuging, organoids pellets were mixed directly with matrigel in the ratio of 1:1 with a 
total volume of 100-200 µl. 4-6 weeks old female NOG/JicTac (CIEA NOD.Cg-Prkdc-scid 
Il2rg-tm1Sug) mice were purchased from Taconic, and subcutaneously injected with the 
collected tumor organoids (transplanted cell number: 1-10×106). Tumor formation was 
monitored weekly and mice were sacrificed to harvest tumor after visualizing the tumor 
(the tumor diameter reached approx.1 cm). Tumor tissues were stored or cultured as 
described above. 
 
2.6. Single organoid formation assay and allograft assay 
Cold medium was used to collect the organoids, and organoids were digested into 
single cells. FACS sorter (BD FACSAriaTM II) was used to isolate the single living cells. 
Propidiumiodide (PI) staining was used to exclude dead cells. FSC-Width with FSC-Area 
and then SSC-Width with SSC-Area gates were used to select the single cells. After 
mixing one single cell with matrigel, a droplet with in total volume of 5 µl was seeded in a 
well of 96-well plate for organoid initiation. After 1-3 weeks, single organoids were formed. 
Cold medium was used to collect the single organoids. After removing the supernatant, 
matrigel was mixed with the organoid pellet and transplanted subcutaneously into the 
NOG mice directly. Tumor formation was monitored as described above. 
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2.7. Metabolic activity analysis of organoids 
Different organoid lines were seeded separately in a 24/48-well plate. Sorafenib (1 µM, 
10 µM) or Regorafenib (1 µM, 10 µM) was added to the organoid culture since the initial 
day or post-initiation day 3, respectively. Drugs were refreshed every 2 days. At the day 7, 
organoids were incubated with Alamar Blue (Invitrogen, 1:20 in DMEM) for four hours, and 
then medium was collected for analysis of the metabolic activity of the cells, which is an 
indirect measure of living cells. Absorbance was determined by using fluorescence plate 
reader (CytoFluor® Series 4000, Perseptive Biosystems) at the excitation of 530/25nm and 
emission of 590/35. Each treatment condition was repeated for four times and matrigel 
only was used as blank control. 
 
2.8. qRT–PCR  
    We performed the qRT–PCR as described previously [11]. In short, Machery-
NucleoSpin RNA II kit (Bioké) was used to extract RNA from organoids. Glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) gene was used as a reference. All primers are listed in 
Supplementary Table 5. 
 
2.9. Statistical Analysis 
Prism software (GraphPad Software) was used for all statistical analysis. We used 
Mann-Whitney U-test and differences were considered significant at a p value less than 
0.05. More details are described in the supplementary materials and methods.  
 
 
 
 
3. Results: 
3.1. Successful culture of organoids from mouse primary liver tumors  
Diethylnitrosamine (DEN) is widely used as a carcinogen in experimental animal models, 
in particular for inducing liver tumors in mice. Similar to the gender disparity in patients, 
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DEN also preferentially induce liver tumors in male mice [12]. Thus, we have mainly used 
male mice (53 male; 3 female) to induce liver tumor by DEN. The livers were harvested for 
organoid culture (Fig. 1A: the upper panel). The numbers of visible tumors vary among the 
harvested mouse livers, ranging from zero to multiple tumors per liver (Supplementary Fig. 
S1). In total, we obtained 128 individual tumors from these mice, which were subjected to 
organoid culture. In general, small organoids could be visualized since post day 2-7 and 
passage was required around 7-14 days. We have succeeded in establishing organoid 
culture from 90 out of the 128 tumors, representing an efficiency of 70.3% (Supplementary 
Table S1). Among the 38 tumors that failed to establish organoid culture, 12 samples did 
initiate organoids but stopped proliferation at an early stage; whereas many of the other 
tumors had extensive necrosis and did not initiate any organoid from the start.  
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Fig. 1. Establishment of long-term cultures of primary mouse liver tumor organoids and 
their further characterization (A) The upper panel: An outline of the experimental strategy used 
to establish primary tumor organoid; The lower panel: Representative pictures showing tumor 
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organoids cultured from mouse primary liver tumors, and the formation of allograft tumor in the 
NOG mice. The allograft tumors can again be cultured into tumor organoids . (B) The upper panel: 
An outline of the experimental strategy used to investigate a single tumor organoid; The lower 
panel: Representative pictures showing that allograft tumor can again initiate tumor organoids . A 
single cell isolated from the tumor organoid can initiate a single organoid and then initiate tumor 
growth in NOG mice. (C) The expression profile of progenitor markers of tumor organoids, 
compared to healthy liver organoids (n=3). (D) Representative immunofluorescence pictures 
showing the expression of CD44 in tumor organoids.  
 
    The successfully established lines could be maintained and propagated in 3D culture for 
at least 5 months (the maximum time period tested so far), by passaging in the ratio of 1:2-
1:4 for every 7 days. We further demonstrated that these tumor-derived organoids can be 
frozen, stored and re-cultured again without affecting their growth rate. With respect to the 
morphology, we (Supplementary Fig. S2A) and others [4] have observed that organoids 
derived from the healthy liver have a uniform, bubble-like structure. In contrast, organoids 
derived from liver tumors presented diverse morphologies, ranging from bubble-like to 
condensed and flower-like, as well as an irregular sheet-like structure (Supplementary Fig. 
S2B-D). Interestingly, some cultures contained a mixture of organoids with different 
morphology (Supplementary Fig. S3A), which may reflect the heterogeneity of cell types 
within the tumors.  
 
3.2. Tumorigenicity of expanded organoids in immunodeficient mice 
To functionally assess whether these tumor-derived organoids are malignant, we 
performed the allograft assay in NOG immunodeficient mice as described previously [13]. 
We have subcutaneously engrafted all the established 90 organoid lines and assessed 
their tumor formation ability in vivo. Within 4-10 weeks, 16 out of 90 (18%) lines initiated 
tumor formation in NOG mice (Fig. 1A: the lower panel and Table 1: the upper panel).  
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Fig. 2. Liver tumor organoids express hepatocyte and cholangiocyte markers (A-C) 
Representative pictures showing the organoid lines that mainly express the hepatocyte marker 
HNF4ɑ (A, n=1), the cholangiocyte marker CK19 (B, n=4) and both (C, n=3), and the 
corresponding H&E staining for the primary tumor (P) and its corresponding allograft tumor (A) and 
the organoids.  
Organoids could be cultured again from these allograft tumors (Fig. 1A: the lower panel). 
These tumor organoids have to be passaged every 5 days in the ratio of 1:5-1:10, 
indicating an increased speed of growth. Importantly, when engrafting into NOG mice, 
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these organoids are capable to readily initiate tumors again (Table 1: the middle panel). 
These results firmly demonstrated that those liver tumor derived organoids are malignant 
and tumorigenic with self-renewal capability.  
 
Table 1. Liver tumor organoids can initiate tumors. The upper panel: The primary tumor 
organoid lines which formed tumor in the NOG mice, and the corresponding information of tumor 
harvesting time and mouse strain; The middle panel: Tumor organoids derived from the allograft 
(1st allograft) can re-initiate tumor again (2nd allograft) in the NOG mice; The lower panel: The 
corresponding tumor harvesting time of single cell formed organoid derived allograft tumors. 
 
3.3. A single organoid derived from a single cancer cell is able to initiate tumor formation in 
mice  
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    To further consolidate the ability to initiate tumor growth of the organoids, we performed 
an organoid formation assay with isolated single cells. We found that isolated single cells 
from the tumor organoids can efficiently re-initiate organoids (Fig. 1B). More importantly, 
subcutaneous transplantation of a single tumor organoid derived from a single cell into 
immunodeficient NOG mice rapidly initiated tumor around two weeks, confirming their 
malignant property (Fig. 1B and Table 1: the lower panel). Furthermore, organoids can be 
re-cultured from those allograft tumors and exhibited progressive expansion for over 4 
months. These results indicate that 3D tumor organoid system enriches the cells with the 
capacity of tumor initiating.  
Classically, stem cell markers have been widely used to identify potential TIC, although 
it is an ever debating issue of defining qualified TIC markers [14]. Based on previous 
studies [14, 15], we have profiled a panel of potential TIC markers, in comparison with liver 
organoids from normal liver stem cells. We found that liver tumor organoids have lower 
gene expression of Sox2, Sox17, Nanog, Oct4, Krt19, Bmi1, Lgr5 and Cd133, relatively 
higher expression of Sox9 and significantly upregulation of Cd44. The expression of CD44 
at protein level was confirmed by immunofluorescent staining (all positive in tested 8 lines), 
indicating that tumor organoids have a different expression profile of these putative 
markers compared to the normal stem cell pool (Fig. 1C-D).  
 
3.4. Tumor organoids express cholangiocyte and/or hepatocyte markers 
    In patients, primary liver cancer has been traditionally classified into three main types 
based on the tumor cell type. These are hepatocellular carcinoma (HCC), 
cholangiocarcinoma (CC) and hepatocellular-cholangiocarcinoma (CHC). Although it 
remains a challenge to differentiate these types, hepatocyte (e.g. AFP, HNF4ɑ) or/and 
cholangiocyte (e.g. CEA, CK19, C-KIT) markers are often used as one of the approaches 
to distinguish these types of liver cancer [16]. In this respect, we have characterized the 
established tumor organoids by staining with hepatocyte (HNF4ɑ) and cholangiocyte 
(CK19) markers, respectively. We found a distinct variation among different lines of 
established tumor organoids. Some with a subset of cells express HNF4ɑ (Fig. 2A), some 
express CK19 (Fig. 2B), and others express both markers (Fig. 2C). In contrast, organoids 
derived from normal liver stem cells often do not express these lineage markers, especially 
HNF4ɑ (Supplementary Fig. S4). These data indicate a distinct phenotype of tumor 
compared to normal organoids, and may recapitulate the heterogeneity of liver cancer 
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types in patients to some extent. Of note, given that the etiology of liver cancer is diverse, 
DEN induced liver tumors in mice do not fully represent liver cancer in patients [12]. 
 
3.5. Assessment of anti-cancer drugs in the tumor organoid model 
   Current treatment options, in particular for advanced liver cancer, are very limited. 
Sorafenib is the only FDA-approved first-line systemic therapy for patients with advanced 
HCC, with improvement of patient survival for only 3 months [1]. Regorafenib is now 
emerging as a potential second-line therapy for HCC patients [17]. To explore the potential 
of using liver tumor organoid models for future drug development, we assessed the 
feasibility by testing the effects of Sorafenib and Regorafenib.  
    We used organoid lines established from eight allograft tumors. We evaluated the 
effects on tumor organoid initiation by treatment with the drugs in the early phase of 
seeding the cells; while the effects on organoid growth were determined by starting the 
treatment at day 3 when the organoids are already formed. 
     Overall, these two targeted therapies dose-dependently inhibited the numbers of 
organoids formed and the growth of the organoids (Fig. 3, Supplementary Table S2 and 
S3). However, we also observed clear variations of the responsiveness among these 
organoids. For instance, organoid initiation of AT72 is sensitive to Sorafenib but less to 
Regorafenib; whereas initiation of AT71 is moderately suppressed by both Sorafenib and 
Regorafenib treatment. AT65 is more sensitive to early treatment; whereas both AT71 and 
AT85 better responded to Sorafenib when treatment was applied after organoids had 
already formed. Taken together, these results reflect the heterogeneity of individual lines 
as well as the differences in responsiveness between treatments at different stages of 
organoid growth. 
 
Fig. 3. Reaction of tumor organoids in response to treatment with the targeted therapeutics 
Sorafenib or Regorafenib (A-B) Eight tumor organoid lines were analyzed here: AT65, AT66, 
AT71, AT72, AT83, AT84, AT85 and AT86. At day 7, the Alamar blue assay was used to measure 
the proliferation of organoids. Organoid number was counted to determine the initiation ability. The 
effects on organoid initiation were evaluated by adding the drugs immediately after seeding the 
cells. The effects on organoid growth were evaluated by adding the drugs 3 days after seeding the 
cells when the organoids had already formed (P<0.05, n=4). (C) Representative pictures taken at 
day 7, showing that tumor organoids respond differently to the treatment (P<0.05, n=4). 
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4. Discussion 
This study has demonstrated the establishment of organoids from primary mouse liver 
tumors. These organoids can be expanded in long-term cultures and initiate tumors in 
immunodeficient mice. Importantly, these organoids recapitulate, to some extent, the 
heterogeneity of liver cancer as seen in patients, with respect to phenotype, cancer cell 
composition and treatment response. 
Classically, the investigation of liver cancer is based on in vitro cell lines, which have 
the following limitations: 1) limited number of established cell lines; 2) low efficiency of 
establishing new lines from primary tissues; 3) only aggressive tumors have high change 
to establish in vitro culture successfully [18]. Thus, the majority of primary tissue (>90%) 
cannot be successfully culture in vitro, especially the benign or less aggressive tumors, 
which also should be further investigated [18].Apart from the traditional cell line culture 
models, several other methods have also been explored to model liver cancer in vitro. The 
rotating wall vessel bioreactor has been used to culture HCC cell lines. This system was 
further used to co-culture the liver tumor cells with colon carcinoma cells to form liver-
tumor hybrid, as a model to mimic liver metastasis [19]. In addition, 2D or 3D spheroid 
culture has been applied to culture HCC cell lines [20, 21]. However, the majority of those 
in vitro systems involve immortalized cell lines, rather than primary tissue.  
We here adopted a matrigel-based 3D organoid culture system. This model allows 
investigation of healthy adult stem cells, as well as various types of diseases, in particular 
cancer. Successful examples have been reported in establishing organoids from colon [6], 
pancreas [7] and prostate tumor tissues [8]. Here we reported that we have succeeded in 
establishing 90 lines from 128 liver tumors. These organoids are capable of long-term 
culture and expansion in vitro. They are capable of initiating tumors in immunodeficient 
mice upon (serial) transplantation, confirming their tumorigenic, malignant and self-renewal 
properties. We also observed different morphology in established tumor organoids. The 
diversity of morphology has previously also been observed in other types of tumor 
organoids, such as those derived from colorectal [6], pancreatic [7] and prostate [8] cancer. 
Our results also support the notion that liver tumors contain TIC, and organoids may 
represent an innovative model system for studying these cancer cells. TIC is a rare cancer 
cell population, but is thought to be the engine of tumor formation, relapse, metastasis and 
chemo-resistance in many cancer types [14], including in liver cancer [22]. We envision 
that these tumor organoid models have potential to circumvent a major bottleneck in the 
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TIC field as these cells are usually not able to be cultured in vitro. The current research is 
largely based on phenotypic description and tumor formation assays in immunodeficient 
mice [22]. Sophisticated in vitro culture of liver tumor organoids that are capable of long-
term propagation ex vivo, as demonstrated in our study, provides a unique tool for the 
research field to advance in-depth research of liver TIC.  
We further reveal the heterogeneity of individual lines as well as the differences in 
responsiveness between treatments at different stages of organoid growth. This provides 
proof-of-concept that organoids have the potential to be used as an in vitro  model to study 
anti-cancer drug development in general, as well as for personalized medicine in cancer 
treatment in particular. Furthermore, TIC have been proposed as attractive anti-cancer 
targets and recent studies have demonstrated the possibility and efficacy of targeting TIC 
in animal models [23]. We believe that tumor organoid models have particular advantages 
as a platform for facilitating the development of TIC targeted therapies, given that these 
cells can be ex vivo cultured from primary tumor tissues [24]. 
The organoid model system may well provide enormous opportunities for advancing 
research on liver cancer/stem cell biology, drug development and personalized medicine. 
Of note, organoid systems do not mutually exclude the use of the classical cancer cell 
lines, but in fact can complement each other. Finally, more efforts are urgently required to 
establish robust organoid models from patient liver tumors.   
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Supplementary Fig. 1. Examples of primary liver tumor (A) liver with one visible tumor. (B) liver 
with more than one tumor. The red arrow depicts the location of tumors.  
 
 
 
 
 
 
Supplementary Fig. 2. Morphology of tumor organoids (A) Example of normal liver organoids. 
(B-D) The tumor organoids with different morphological aspects. 
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Supplementary Fig. 3. Tumor organoids show mixed or uniform morphology. AT86 show 
mixed morphology and AT83 show uniform morphology (Left: H&E staining, 25×; Right: bright view, 
100×). 
 
 
 
 
 
 
Supplementary Fig. 4. The normal organoid do not express HNF4ɑ. Left panel: negative 
control for the antibody; Middle panel: healthy liver tissue expresses HNF4ɑ; Right panel: the 
healthy organoids do not express HNF4ɑ (40×). 
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Supplementary Table 1. Tumor organoid lines. All the 90 tumor organoid lines, for the genetic 
background, gender and primary tumor formation time (counted since the time of first Den injection 
until the time to sacrifice the mice). 
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Supplementary Table 2. Tumor organoids respond differently to drugs. Inhibition of growth in 
response to drug treatment is depicted relative to the untreated group and divided in three 
categories: weak inhibition (100%-60%, ↓), moderate inhibition (60%-40%, ↓↓) and strong 
inhibition (40%-0%, ↓↓↓).  
 
 
Supplementary Table 3. Tumor organoids respond differently to the drug. For the inhibition of 
the organoid initiation, response to the drug was exhibited by the relative initiated organoid number 
compared to the drug-untreated group and also divided into three categories: weak inhibition 
(100%-50%, ↓), moderate inhibition (50%-20%,↓↓) and strong inhibition (20%-0%, ↓↓↓). 
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Antibody Antibody clone/ 
reference 
Raised Origin 
HNF4ɑ sc-8987 X Rabbit STCruz 
CK19 ab52625 Rabbit Abcam 
CD44 ab157107 Rabbit Abcam 
Donkey anti-Rabbit 
IgG (H+L) Secondary 
Antibody, Alexa 
Fluor® 594 conjugate 
A-21207 Donkey Thermo fisher 
 
Supplementary Table 4. The antibodies employed in this study 
  
 
 
93 | P a g e  
 
Gene name Gene 
Symbol 
Sequence 
Leucine-rich repeat-containing G-protein 
coupled receptor 5 
Lgr5 fw CTG ACT TTG AAT GGT GCC TCG 
re ATG TCC ACT ACC GCG ATT AC 
Antigen Cd44 Cd44 fw CGT CCA ACA CCT CCC ACT AT 
re AGC CGC TGC TGA CAT CGT 
Transcription factor SOX-9 Sox9 fw CGA CTA CGC TGA CCA TCA GA 
re GAC TGG TTG TTC CCA GTG CT 
SRY (sex determining region Y)-box 17 Sox17 fw GGC GCA GCA GAA TCC AGA 
re CCA CGA CTT GCC CAG CAT 
Antigen Cd133 Cd133 fw  TCT GTT CAG CAT TTC CTC AC 
re  TCA GTA TCG AGA CGG GTC 
Transcription factor Nanog Nanog fw AGG GTC TGC TAC TGA GAT GCT 
CTG 
re CAA CCA CTG GTT TTT CTG CCA 
CCG 
Octamer-binding transcription factor 4 Oct4 fw CTG TAG GGA GGG CTT CGG GCA 
CTT 
re CTG AGG GCC AGG CAG GAG CAC 
GAG 
SRY (sex determining region Y)-box 2 Sox2 fw GGC AGC TAC AGC ATG ATG CAG 
GAG C 
re CTG GTC ATG GAG TTG TAC TGC 
AGG 
Cytokeratin-19 Krt19 fw GTG AAG ATC CGC GAC TGG T 
re AGG CGA GCA TTG TC AAT CTG 
Polycomb complex protein Bmi1 fw TTC ATT GAT GCC ACA ACC AT 
re CAG CAT CAG CAG AAG GAT GA 
 
Supplementary Table 5. The primers employed in this study 
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Abstract: 
Background & Aims: Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) 
is a recently identified marker for a liver stem cell population. However, the existence and 
function of LGR5 cells in liver cancer has not been demonstrated. Here we investigate the 
role of hepatic LGR5-expressing cells in liver tumors.  
Methods: A LGR5-promotor driven diphtheria toxin (DT) receptor knock-in mice model 
with a GFP reporter were used. Carbon tetrachloride (CCL4) was used to induce chronic 
liver injury and diethylnitrosamine (DEN) was used to induce primary liver tumors in mice. 
Results: We observed that the carcinogen DEN induces a liver LGR5-positive stem cell 
compartment. In thus-induced hepatic tumors, the percentage of LGR5 cells is significantly 
higher as compared to tumor adjacent tissue (n=28, P< .05, 3-fold higher), and this even 
more apparent when compared to tissue of CCl4-induced chronic injury (n=28, P<0. 001, 
52-fold higher). Tumor organoids generated by ex vivo culturing of primary mouse liver 
tumor contain an LGR5-expressing cell population. Subcutaneous transplantation of these 
tumor organoids into immunodeficient NOG mice results in solid tumors, which retain a 
LGR5 positive compartment. Isolation and culturing of single LGR5+ cell from primary 
mouse tumor initiated tumor organoids, and transplantation of these organoids into NOG 
mice formed tumor again. Thus, these cells have cancer initiating/stem cell-like properties. 
Importantly, LGR5 cancer cells are resistant to therapeutic agents and specific depletion of 
these cells impedes the growth of liver tumors in vivo. 
Conclusion: Hepatic LGR5 stem cells contribute to DEN-induced liver carcinogenesis and 
LGR5 marks tumor initiating cells. Thus targeting LGR5-positive cells appears promising 
as an anti-cancer strategy in the liver. 
 
Keyword: LGR5, Tumor stem cell, Tumor organoid, Liver tumor 
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Introduction 
The key concept of cancer stem cell theory is that tumor contains a hierarchical structure 
with different functional populations of cells 1. The bulk of a tumor consists of cancer stem 
cells as well as rapidly proliferating cells. Cancer stem cells are responsible for tumor 
initiation and fueling the growth of tumor continually, as well as responsible for the local 
tumor recurrence and distant metastasis. Rapidly proliferating cell are responsible for 
enlarging the volume of the tumor and are thought to be derived from the tumor stem cell 
pool.  
Classically, the identification of cancer stem cells is based on the following features: 1) 
strong self-renewal capability; 2) differentiation into different types of cells; 3) resistance to 
treatment. Those are also the key features of normal stem cells. Thus, normal stem 
cell/embryonic stem cell markers are widely used to identify cancer stem cells 2. LGR5 
(leucine-rich repeat-containing G protein-coupled receptor 5) is a well-characterized stem 
cell marker in several organs, including the intestine, the colon and the liver 3-5. In the 
colon and the intestine, the LGR5 stem cell pool regularly proliferates to compensate for 
the loss of functional cells. Interestingly, LGR5 stem cells from colon/intestine are already 
reported to participate in the tumor formation and progression, acting as cancer stem cell/ 
tumor initiating cells 6-8. In adenoma as well as malignant carcinoma, LGR5 cells account 
consistently for a ratio of 10%-25% 6, 9. Considering the notion that cancer stem cells are 
relatively resistant to the regular treatment, the development of new treatment targeting 
cancer stem cells is attractive. It has been reported that elimination of colorectal cancer 
LGR5 cells can delay the growth of the colon cancer, without major impact on the function 
of normal LGR5 stem cells 7.  
In contrast to the colon/intestine, liver LGR5 cells are not present in normal liver 
homeostasis, but emerge upon liver injury. Thus, liver LGR5 cells are classified as an 
injury response stem cell population 10. However, the existence and function of LGR5 cells 
in liver cancer remain largely elusive. Thus, this study aims to investigate whether liver 
LGR5 cells participate in tumor formation and progression, and whether represent as a 
therapeutic target for treating liver cancer.  
 
 
Materials and Methods 
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Primary liver tumor model 
    Lgr5-DTR-GFP transgenic mice (kindly provided by Genentech) specifically co-express 
the diphtheria toxin (DT) receptor (DTR) and Green florescent protein (GFP) under the 
control of the Lgr5 promotor 11. Thus, LGR5+ cells will be identified by GFP, and LGR5-
GFP+ cells can be specifically depleted by DT administration. Lgr5-DTR-GFP transgenic 
mice (3-4 weeks) were administrated with Diethylnitrosamine (DEN) by intraperitoneal 
injection (i.p., 100 mg/kg) weekly for 6-17 weeks. Mice were sacrificed 3-16 months after 
the last DEN injection and livers/tumors were collected for further experiments. All animal 
experiments were approved by the Committee on the Ethics of Animal Experiments of the 
Erasmus Medical Center. 
 
Tumor Organoid Culture 
Digestion solution II (37°C, 30 min, 500 µg/ml of collagenase type XI, 200 µg/ml of 
Dnase-1, 1% FBS in DMEM medium) was used to digest liver or tumor tissues into single 
cell suspension. Single cell suspension was directly mixed with matrigel and then used for 
culturing, or further sorted for further experiments. Sorted cells were also mixed with 
matrigel and seeded for organoid initiation. Cells were cultured in organoid culture medium 
as previously published 10, 12. For the first 8-12 days, the organoids were supplemented 
with 10 μM Y-27632 (Sigma-Aldrich), Noggin and Wnt3a conditioned medium. Medium 
was refreshed every 2 days and passage was performed in split ratios of 1:2-1:15 weekly.  
 
Histology, Immunohistochemistry and Immunofluorescence 
    Liver or tumor was fixed in 4% paraformaldehyde (PFA) overnight at 4°C. For 
immunofluorescence, samples were further dehydrated with 30% sucrose (Sigma-Aldrich, 
4°C, overnight), stored at -80°C and then sectioned at 8 μm for further analysis. Images 
were acquired with a Zeiss LSM510META confocal microscope. For histology and 
immunohistochemistry, materials were dehydrated with 70% ethanol, embedded with 
paraffin, sectioned at 4 μm for staining. Images were acquired with a Zeiss Axioskop 20 
microscope. All antibodies are listed in Supplementary Table 1. 
 
Organoid allografting 
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    Cold advanced DMEM/F12 medium was used to collect the organoids. After 
centrifuging, supernatant was discarded and organoids pellets were mixed directly with 
matrigel in the ratio of 1:1 with a total volume of 200 µl. 4-6 weeks old female NOG/JicTac 
(CIEA NOD.Cg-Prkdc-scid Il2rg-tm1Sug) mice or nude mice (NMRI:BomTac- Nude) were 
purchased from Taconic, and subcutaneously injected with the collected tumor organoids. 
Tumor dimensions were measured using calipers and tumor volume was calculated as 
0.523× length× width× width 7. Tumor formation was monitored every other day and mice 
were sacrificed to harvest tumor after the tumor diameter reached approx.2 cm. Tumor 
tissues were stored or cultured as described above. 
 
Diphtheria Toxin-mediated Cell Ablation 
To ablate LGR5+ cells in organoids, DT (1-10 ng/ml) was added to organoid 
expansion/initiation medium, followed by further analysis 12. For in vivo ablation, DT was 
administrated via intraperitoneal injection every other day (50 µg per kg). If mice suffer 
from weight loss≥10%,compared to the previous injection, the injection was omitted.  
 
FACS Analysis  
    For FACS analysis, single cells derived from liver and organoids were suspended in 
DMEM plus 2% FBS. Cell suspensions were analyzed using a BD FACSCalibur or BD 
FACSAriaTM II. For FACS sort, a BD FACSAriaTM II cell sorter was used to isolate the 
target cell population. Propidium iodide (PI) staining was performed to exclude dead cells 
and CD45 staining was adopted for excluding leucocytes. 
 
Metabolic activity analysis of organoids 
    Different organoid lines were seeded separately in a 24/48-well plate. Sorafenib (10 µM) 
or 5-FU (10 µM) was added to the organoid culture since the initial day or post-initiation 
day 3, respectively. Drugs were refreshed every other day. At the day 6-7, organoids were 
incubated with Alamar Blue (Invitrogen, 1:20 in DMEM) for four hours (37°C), and then 
medium was collected for analysis of the metabolic activity of the cells. Absorbance was 
determined by using fluorescence plate reader (CytoFluor® Series 4000, Perseptive 
Biosystems) at the excitation of 530/25nm and emission of 590/35. Each treatment 
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condition was repeated for four times and matrigel with medium only was used as a blank 
control. 
 
Statistical Analysis. 
Prism software (GraphPad Software) was used for all statistical analysis. For statistical 
significance of the differences between the means of groups, we used a Mann-Whitney U-
test. Differences were considered significant at a P value less than 0.05.  
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Results 
DEN-induced primary liver tumors contain LGR5 expressing cells  
Employing Lgr5-DTR-GFP knock-in mice (Figure 1A), we first confirmed that LGR5+ cells 
(GFP expressing cells) are absent in the healthy liver. We then induced primary liver 
tumors by repeated administration of carcinogen compound DEN (Figure 1B). We 
observed that single/repeated administration of DEN triggered the emergence of LGR5-
GFP+ cells in the liver within a short period (mean ± SEM, 1 × DEN: 0.025 ± 0.05%, n = 3) 
(Supplementary Figure 1A-B). After 4-14 months of tumor formation, we found that LGR5 
expressing cells remained stably present in the liver tumor, as well as in tumor surrounding 
tissues (Figure 1C). Liver tumors (7.3 ± 1.7%, N=58) have significantly higher percentage 
of LGR5-GFP+ cells compared to tumor surrounding tissues (2.4 ± 1.1%, N=29). 
Compared to the liver injured with single/repeated CCl4 and livers in physiological 
homeostatis, the DEN-treated livers have significantly upregulated percentages of LGR5 
cells (Figure 1D). We observed that the percentages of LGR5-GFP+ cells within liver tumor 
varied from 0.081% up to 55.6% (Supplementary Figure 1C-D). The expression level of 
tumor LGR5 also showed different levels of upregulation compared to injury induced LGR5 
expressing cells (Figure 1E). Both anti-GFP immunohistochemistry and 
immunofluorescence depended on the GFP expression both confirmed the expression of 
LGR5-GFP (IF: Figure 1F; IHC: Supplementary Figure 1E-F). We also observed different 
types of localization of LGR5-GFP+ cells (IF: Figure 1F; IHC: Supplementary Figure 1E-F). 
After co-staining with hepatocyte marker (HNF4ɑ) or cholangiocyte marker (CK19) 
respectively by immunofluorescence, we found that LGR5-GFP+ cells can express 
hepatocyte or cholangiocyte markers (Figure 1G-H). Thus, these data demonstrated that 
LGR5+ cells are present in DEN induced primary murine liver tumors.  
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Figure 1: LGR5 expressing cells are present in the DEN-induced primary liver tumors. (A) A 
schematic of the Lgr5-DTR-GFP transgenic mouse model used. (B) An outline of the experimental 
strategy used. (C) LGR5+ cells showed significant upregulation in liver tumor, compared to tumor 
surrounding tissue (*P < .05). S: tumor surrounding tissues; T: tumors. (D) LGR5+ cells showed 
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significant upregulation in DEN induced liver, compared to healthy liver and CCL4 induced injured 
liver (*P < .05). N: normal liver; I: CCL4 injured liver; T: DEN induced liver. (E) Liver tumor LGR5
+ 
cells showed enhanced fluorescence intensity compared to healthy liver LGR5+ cells. (F) 
Representative pictures showing LGR5 cells existed in liver tumors, which indicated by anti-GFP 
immunofluorescence staining; Yellow arrow: LGR5+ cell. DAPI: blue. (G) Representative confocal 
images for the expression of hepatocyte-specific marker (HNF4ɑ, red) and cholangiocyte marker 
(CK19, yellow) in LGR5-GFP expressing cells.  
 
Allograft liver tumors sustain LGR5 cells 
To further characterize the LGR5 expressing compartment in liver tumor, we established 
organoid cultures from primary liver tumors. After tumor formation, murine liver tissues 
were collected and cultured with matrigel in a 3D system (Supplementary Figure 2A). In 
total, 66 organoid strains were obtained from 37 independent livers. The successfully 
established lines could be maintained and propagated in 3D culture for at least 5 months 
(the maximum time period tested so far), by passaging in the ratio of 1:2-1:4 for every 7 
days. With respect to the morphology, organoids derived from liver tumors presented 
diverse aspects, ranging from a normal outlook, to bubble-like (Supplementary Figure 2C), 
condensed (Supplementary Figure 2D), and flower-like, irregular sheet-like structures 
(Supplementary Figure 2E).  
 
 
 
 
Figure 2: Allograft liver tumors sustain the expression of LGR5. (A) The expression of LGR5 in 
allograft tumor and the corresponding primary tumor. (B) The distribution of LGR5 expression 
percentages in allograft tumors and the corresponding primary tumors. (C) Representative pictures 
showing LGR5 cells existed in allograft liver tumors, which indicated by anti-GFP 
immunohistochemistry staining. LGR5+ cell: Brown; DAPI: blue. (D-E) Representative pictures 
showing the organoid lines that mainly express the hepatocyte marker HNF4ɑ (D) and the 
cholangiocyte marker CK19 (E). (F-G) Representative pictures showing the HCC (F) and CC (G) 
organoid lines. 
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To further confirm that these organoid strains were indeed malignant, we transplanted 
the organoid into immunodeficient NOG mice (Supplementary Figure 2A). After 1-6 
months of tumor formation, 12 out of 66 strains of the organoid formed tumor (18.2%). We 
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further collected the allograft tumors and checked the Lgr5 expression by FACS machine. 
The FACS results indicated that the expression of LGR5 is retained in the allograft tumors 
(Figure 2A-C). We also collected the allograft tumor and cultured these into organoids 
again. After 1-3 days of culturing, small organoids could be observed and passaging was 
performed every 4-7 days, in a ratio of 1:4-1:20. We further stained these allograft tumor-
initiating organoids with CK19 and HNF4ɑ respectively, to establish whether these 
organoids are of a cholangiocyte carcinoma (CC) or a hepatocellular carcinoma (HCC)-like 
phenotype (Supplementary Figure 2F). Among these tumor initiating organoid strains, 2 
out of 12 were HCC-like; 10 out of 12 were CC/CHC-like. This CK19 and HNF4ɑ staining 
of the corresponding allograft tumors also further confirmed the tumor type (Figure 2D). 
The expression of LGR5 is maintained in the organoid cultures (Supplementary Figure 2G). 
In conjunction these results indicate that LGR5 cells are constitutively present in allograft 
liver tumors. 
 
Single LGR5 cells from liver tumor have a relative large organoid 
initiating ability 
To functionally characterize LGR5 liver tumor cells, we carried out an organoid initiation 
assay, that measures the clonogenic ability of single LGR5 expressing cells. By using 
FACS, LGR5-GFP+ and LGR5-GFP- cells were sorted from liver tumors, and cultured in 
3D matrigel (Figure 3A and Supplementary Figure 3A). After 2-3 weeks of organoid 
formation, we observed that LGR5-GFP+ cells can form organoids and have a larger 
organoid forming ability compared to LGR5-GFP- cells (LGR5+: 1.9 ± 0.7% Vs. LGR5-: 0.1 
± 0.1%, N=25) (Figure 3B-C).  
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Figure 3: Single LGR5 cells have strong organoid initiation ability in vitro. (A) An outline of the 
experimental strategy used. (B) Representative pictures showing single LGR5+ cells initiated 
organoids from CC (Left) and HCC (Right) tumors. (C) The organoid initiation efficiency of LGR5-
GFP+ and LGR5-GFP-, isolated from primary liver tumor (*P < .05). (D) An outline of the 
experimental strategy used. (E) The organoid initiation efficiency of LGR5-GFP+ and LGR5-GFP-, 
isolated from allograft liver tumor (*P < .05). (F) Representative pictures showing that single LGR5+ 
cells can initiate organoids which can give birth to both LGR5+ and LGR5- offspring. 
We also performed this organoid initiation assay on allograft tumors (Figure 3D). The 
LGR5-GFP+ cells derived from allograft tumors also have more organoid initiating ability as 
compared to LGR5-GFP- cells (LGR5+: 40.5 ± 10.2% Vs. LGR5-: 10.9 ± 4.2%, N=10 
(Figure 3E-F). These single LGR5-GFP+ cells-initiated organoids maintained a LGR5 
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positive compartment, but also gave birth to LGR5 negative offspring,indicating a possible 
hierarchical structure (Figure 3F). Thus, these results indicate that LGR5+ cells have larger 
organoid forming ability when compared to the LGR5- pool of cells. 
 
LGR5+ cells can initiate tumors in vivo 
To further investigate the tumor initiating ability of LGR5+ tumor cells, we performed an in 
vivo tumor formation assay. Upon isolation by FACS, we transplanted the same number of 
LGR5+ and LGR5- cells directly into the NOG mice (Figure 4A). After 1-6 month of tumor 
formation, we observed that LGR5+ showed stronger tumor initiating capacity as compared 
to LGR5- cells (n = 3, Figure 4B). We further harvested these tumors and tested the LGR5 
expression using GFP expression as a surrogate by FACS. We found that the LGR5+ cells 
initiated tumors that contained both an LGR5+ and LGR5- population (Figure 4C and H). 
Anti-GFP immunohistochemistry and immunofluorescence also showed the existence of 
LGR5 positive cells, as well as the LGR5 negative cells, in LGR5+ cells initiated tumors 
(Figure 4I-J). Thus, these results indicated that LGR5-expressing cells have more tumor 
initiating capacity as compared to LGR5- cells. 
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Figure 4: LGR5+ cells can initiate tumors in vivo. (A) The outline of the experimental strategy used. 
(B) The exact weight of tumors initiated by LGR5+ and LGR5- cells. (C) The LGR5 expression in 
single LGR5+ cells initiated allograft tumors and corresponding primary tumors. (D-H) 
Representative pictures showing that LGR5-GFP+ and LGR5-GFP- cells (E) were both isolated 
from DEN-induced primary liver tumor (E). An LGR5-GFP+ cell-initiated allograft tumor after five 
months (F-G). The initiated allograft tumor sustained LGR5 expression (H). (I-J) Representative 
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immunohistochemistry (I) and immunofluorescence (J) pictures showing the presence of LGR5 in 
sorted LGR5+ cells in an allograft tumor, employing anti-GFP staining as a surrogate marker; 
Yellow arrow: LGR5+ cell; DAPI: blue; Green: LGR5+ cell.`  
 
LGR5 expressing cells are more resistant to treatment. 
Tumor initiating/stem cells are thought to be relatively resistant to treatment. Currently, the 
only FDA-approved drug for treating HCC is Sorafenib. Thus, we first investigate how 
LGR5+ liver tumor cells respond to Sorafenib (Figure 5A). Considering that primary tumor 
organoid strains may contain untransformed cells as well, we employed for these 
experiments the allograft tumor strains which have confirmed malignant potential. We 
observed that the treatment of Sorafenib increased the relative size of the LGR5 positive 
compartment (Figure 5B-D). An even more profound increase of LRG5 cells was observed 
under treatment with the chemotherapeutic agent, 5-FU (Figure 5A) (Figure 5C-D). We 
then further evaluated how LGR5+ liver tumor cells respond to treatment in vivo (Figure 
5E). Similar results were observed (Figure 5F). Thus, LGR5-expressing cells from liver 
tumors are relatively resistant to treatment. 
 
Targeting LGR5 inhibits the growth of tumor organoids  
To explore the therapeutic potential of targeting LGR5 cells in liver cancer, we first 
investigated whether specific depletion of LGR5 will influence organoid expansion in vitro. 
Because the Lgr5-DTR-GFP mice co-express DTR, LGR5-GFP+ cells can be specifically 
depleted by DT administration (Figure 6A). In agreement with our previous research, 1 -10 
ng/ml of DT can deplete the LGR5 in the healthy organoid culture with a high efficiency 12. 
Thus, we adopted a similar strategy of DT treatment of tumor organoids to study the 
effects of depletion of LGR5 cells on organoid growth. To this end, we evaluated the 
effects on organoid initiation and expansion through treating with DT at initiating the 
culture or at post passage day 3. Interestingly, we observed that the depletion of LGR5-
expressing cells inhibited the growth of the tumor organoids and that these effects 
correlated to the initial relative size of the LGR5+ compartment. Cultures of organoid 
strains with higher percentages of LGR5 cells were relatively more sensitive to the DT 
(Figure 6D and F). In contrast, the initiation and expansion of organoid strains with 
relatively lower percentages of LGR5 cells were not significantly affected by DT treatment 
(Figure 6E and G). As a control: DT treatment did not influence the initiation and 
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expansion of the wide type tumor organoids (Figure 6C). Thus, these results revealed that 
depletion of LGR5 cells inhibited tumor organoid formation and growth.  
 
Figure 5: LGR5 expressing cells are more resistant to treatment. (A) An outline of the experimental 
strategy used to investigate how Lgr5 expressing cells respond to treatment in vitro. (B) LGR5-
GFP+ cells become significantly more frequent upon administration of Sorafenib and 5-FU. **P< 
0.01, ***P< 0.001. (C-D) Representative FACS plots (C) and confocal pictures (D) indicating that 
LGR5-GFP+ cells were upregulated upon administration of Sorafenib and 5-FU. (E) An outline of 
the experimental strategy used to investigate how Lgr5 expressing cells respond to treatment in 
vivo. (F) LGR5-GFP+ cells become more frequent upon administration of Sorafenib and 5-FU in 
vivo. *P< 0.01.  
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Figure 6: Targeting LGR5 cells can inhibit the growth of tumor organoids in an effect that 
correlates to the initial size of the LGR5+ compartment. (A-B) The outlines of the experimental 
strategies used. (C) The response of wide type tumor organoids to DT administration. The Alamar 
blue assay was used to measure the proliferation of organoids. (D) The response of Lgr5-DTR-
GFP mice derived tumor organoids to DT administrations, which initially have high LGR5 
expression. DT-I: DT administration at the start of the experiment; DT-M: DT administration 
initiated at half of the observation time; C: control organoid without adding DT. (E) The response of 
Lgr5-DTR-GFP mice derived tumor organoid to DT administration, which initially have relatively low 
LGR5 expression. DT-I: DT administration initiated at the start of the experiment; DT-M: DT 
administration initiated at half of the observation time; C: control organoids without adding DT. (F-G) 
Representative FACS plots showing that LGR5-GFP+ cells are depleted by DT administration, for 
high LGR5 expression organoid strains (F) and low LGR5 expression organoid strains (G). 
 
Targeting LGR5+ cells inhibits tumor growth in vivo.  
We next assessed the potential of targeting LGR5 cancer cells in vivo. Upon transplanting 
tumor organoids into immunodeficient mice, we first evaluated the effect of DT treatment 
after formation of visible tumors (Supplementary Figure 4A). We found that the depletion of 
LGR5 cells inhibited the growth of tumors, but the effect was moderate (Supplementary 
Figure 4B-C). In contrast, administration of DT directly following transplantation of tumor 
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organoids (Figure 7A) effectively delayed tumor formation and inhibited their growth 
(Figure 7B). After 10-16 days, tumors were collected and further analyzed by FACS. We 
confirmed the LGR5-depleted tumors were indeed smaller compared to the control group 
(Figure C and D) and that LGR5 cells were depleted in the tumors by the DT treatment 
(Figure 7E). When the DT administration strategy was tested on wild type tumor organoids, 
no significant inhibition of growth was observed (Supplementary Figure 5A-C). These 
results demonstrated that LGR5+ cells are very important in the tumor initiation phase and 
ablation of LGR5+ cells  inhibits the growth of tumors in vivo. We further investigated the 
possibility of combination therapy. We observed that the 5-FU&DT co-treatment can 
significantly inhibit tumor growth, compared to any single-agent treatment (Figure 8A-D).  
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Figure 7: Targeting LGR5+ cells can inhibit tumor growth in vivo. (A) The outline of the 
experimental strategy used. (B) Representative pictures showing tumor volumes of control group 
and the DT-administrated group. (C) The exact weights of tumors of the control (C), 5-Fu- (5), 
Sorafenib- (S) and DT- (D) challenged groups, at the day of mice sacrifice. (D) Representative 
pictures showing the morphological aspect of tumors of the control group and the DT-administrated 
group, from the day of mice sacrifice. (E) Representative FACS plots showing that LGR5+ cells 
were depleted by DT administration.  
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Figure 8: Combination therapy can significantly inhibit tumor growth. (A) The outline of the 
experimental strategy used. (B) Representative tumor growth curves showing tumor volumes of the 
control, the 5-FU, the DT and the 5-FU & DT co-treatment group. C: control group; 5: 5-FU-
administrated group; D: DT-administrated group; 5+D: 5-FU & DT co-treatment group. (C) The 
exact weights of tumors from the control, the 5-FU, the DT and the 5-FU & DT co-treatment group, 
at the day of mice sacrifice. *P< 0.05, **P< 0.01. (D) Representative pictures showing the photos of 
tumors from different groups.  
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Discussion 
This study has demonstrated that LGR5 expressing cells are present in DEN-induced 
liver tumors and represent the cancer stem/tumor initiating cell population. We observedd 
that these cells have more organoid initiating capacity in vitro and more tumor initiating 
capacity in vivo. Interestingly, we found that depletion of LGR5 cells can impede the 
growth of liver tumors.  
Although LGR5 has been reported to mark injury response stem cells in the liver 10, 12, 
the presence and function of these cells in liver cancer remains largely unknown. 
Overexpression of LGR5 has been reported in patient HCC, and these cells appear 
especially enriched in β-catenin-mutated liver tumors 13. However, those observations are 
based on mRNA expression only, due to the lack of reliable anti-LGR5 antibodies. Thus, 
an strong point of the present study is the use transgenic mice which can efficiently label 
the LGR5 expressing cells with GFP and can conditionally ablate LGR5-expressing cells 
with DT-DTR system 11. This model allows the identification and direct visualization of 
LGR5 expressing cells based on the GFP, as well as isolation of LGR5-GFP+ cells for 
further functional analyses and detailed characterization.  
In intestinal adenomas, LGR5 marks 5-10% of the cells and these appear to sustain the 
growth of established adenomas 9. Here we demonstrate that similar to colon/intestinal 
cancer, LGR5-expresing cells are present in DEN induced primary liver tumors. The 
percentage of LGR5-GFP+ cells within the liver tumors varied from 0.1% up to 55% (7.3 ± 
1.7%, N=58). In colon cancer, the percentage of LGR5 tumor initiating cells has been 
reported to be associated with different backgrounds of the tumors, and especially with the 
accumulation of certain oncogenic mutations 6. Thus, the large variation of LGR5-GFP+ 
cells within liver tumors is conceivably related to the different types of oncogenic mutations, 
which deserves further investigation.  
Targeting cancer stem cells is thought to be an important strategy for effective anti-
cancer therapy. The reason is that cancer stem cells appear highly tumorigenic, therapy 
resistant and can differentiate into different types of tumor cells 14. Here we also show that 
the depletion of LGR5 cells can postpone the fast growth phase of the liver tumors 
following transplantation. However, if the depletion starts after the tumor formation has 
been initiated, inhibition is very limited. The possible reason could be that the LGR5+ cells 
represent a very low percentage in well-established tumors, only around 1%. However, if 
the depletion started at an early stage of tumor initiation, the inhibition achieved is more 
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significant. As is also widely accepted, we feel that the xenograft/allograft tumor assay is 
most reminiscent to cancer metastasis 1. Thus, our results indicated that the LGR5 tumor 
stem cells play clinically a more important function when initiating new tumors. This result 
is consistent with earlier findings in colorectal cancer, where results with LGR5+ cells are 
interpreted to be especially relevant for understanding metastasis 6. Those results, in 
conjunction with the data presented here, may hint that the cancer stem cell targeted 
therapy could be very effective, when applied after surgical resection in preventing tumor 
recurrence.  
Several pharmaceutical companies are investigating therapies aimed at eliminating the 
cancer stem cell population. The main strategies include: 1) using antibody-drug 
conjugates to ablate cancer stem cells 7; 2) targeting quiescent cancer stem cells 15; 3) 
inhibiting key pathway with special relevance for cancer stem cell physiology 14. However, 
the de-differentiation of LGR5 negative to LGR5 positive cells has been postulated to limit 
the potential efficacy of targeting LGR5 for treating colorectal cancer 6. Thus, combination 
therapies are probably necessary to exert optimal therapeutic effects. With the intention to 
support expansion of the stem cell pool, Cetuximab has been used to increase the size of 
the LGR5-positive compartment. Then, the ablation of cancer stem cells is executed in 
effort to treat the tumor. This combination therapy has stronger effect on the tumor 
regression than either treatment alone 8. We here also illustrated the possibility of 
combination therapy in treating liver cancer by 5-FU and DT co-treatment (Figure 8A-D). 
Thus, it is important to further identify new therapies or combined treatments which can 
both kill the cancer stem cells and prevent the tumor re-growth.  
In summary, our study illustrated the existence of LGR5 cells in liver tumors and 
functionally proved that LGR5 represented as a liver tumor initiating cell population. The 
depletion of LGR5 can inhibit the growth of tumor in vivo. It will be of particular interest to 
further study targeting LGR5 tumor initiating cell based treatment.   
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Supplementary Figure 1: LGR5 expressing cells present in the DEN-induced primary liver tumors. 
(A) LGR5+ cells present in the liver immediately following DEN administration. (B) Representative 
FACS plots showing that LGR5+ cells are present in the liver upon DEN administration. (C) The 
distribution of the percentages of LGR5+ cells within in liver tumors. (D) The distribution of the 
percentage of LGR5+ cells within in liver tumor surrounding tissues. (E-F) Representative 
immunohistochemistry pictures showing the different distribution pattern of LGR5+ cells in liver 
tumor, as assessed by anti-GFP immunohistochemistry staining; LGR5+ cell: brown; Nuclei: blue.   
122 | P a g e  
 
 
Supplementary Figure 2: Allograft liver tumors sustain the expression of LGR5 expressing cells. 
(A) The outline of the experimental strategy used. (B) Representative picture showing the 
morphology of a normal liver organoid. (C-E) Representative pictures showing the different 
morphologies observed in liver tumor organoids. (F) Representative confocal images for the 
expression of hepatocyte-specific marker (HNF4ɑ, red) and cholangiocyte marker (CK19, yellow) in 
tumor organoids. (G) Representative confocal images showing the expression of LGR5-GFP in 
tumor organoids 
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.  
Supplementary Figure 3: Single LGR5 cells have a relatively strong organoid initiating ability in 
vitro. (A) The FACS testing/sorting strategy of LGR5-GFP+ and LGR5-GFP- cells from 
liver/organoids. (B) Representative pictures showing organoids derived from single LGR5+ cells 
isolated from allograft tumors. (C) The distribution of the percentage of LGR5+ cells isolated from 
primary liver tumors. (D) The cell number distribution for the sorted LGR5+ cells which can initiate 
organoids, employing primary tumors as source material. (E) The distribution of the percentages 
observed of LGR5+ cells as isolated from allograft liver tumors. (F) The cell number distribution of  
sorted LGR5+ cells that can initiate organoids, employing allograft tumors as source material.   
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Supplementary Figure 4: Targeting LGR5+ cells can inhibit tumor growth in vivo. (A) The outline 
of the experimental strategy used. (B-C) Representative tumor growth curve showing t the tumor 
volumes of control group and DT-challenged group in which DT treatment  commenced at day 8.  
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Supplementary Figure 5: DT administration did not have a significant influence on wild type tumor 
organoid-derived tumors. (A) The exact tumor weights of control tumors derived from wild type 
tumor organoid and DT treated group. (B) The tumor growth curve for the control and the DT 
treated group. (C) Representative picture showing the tumors from the control and the DT treated 
group.  
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Supplementary Table 1.  
Antibody Antibody clone/ 
reference 
Raised Origin 
CD45 56-0451-82 Mouse eBioscience 
GFP A-11122 Rabbit Invitrogen/Life 
Technologies 
HNF4ɑ sc-8987 X Rabbit STCruz 
CK19 ab52625 Rabbit Abcam 
Alexa Fluor® 488 
AffiniPure Donkey Anti-
Goat IgG (H+L) 
705-545-147 Donkey Bio-Connect 
 
Donkey anti-Rabbit IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
594 conjugate 
A-21207 Donkey Thermo fisher 
Donkey anti-Goat IgG 
(H+L) Cross-Adsorbed 
Secondary Antibody, 
Alexa Fluor 594 
A-11058 Donkey Thermofischer 
Donkey anti-Goat IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
647 conjugate 
A-21447 Donkey Life Technologies 
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Abstract 
As uncontrolled cell proliferation requires nucleotide biosynthesis, inhibiting enzymes that 
mediate nucleotide biosynthesis constitutes a rational approach to the management of 
oncological diseases. In practice, however, results of this strategy are mixed and thus 
elucidation of the mechanisms by which cancer cells evade the effect of nucleotide 
biosynthesis restriction is urgently needed. Here we explored the notion that intrinsic 
differences in cancer cell cycle velocity are important in the resistance towards inhibition of 
inosine monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA). In short-
term experiments, MPA treatment of fast-growing cancer cells effectively elicited G0/G1 
arrest and provoked apoptosis thus inhibiting cell proliferation and colony formation. 
Forced expression of a mutated IMPDH2, lacking a binding site for MPA but retaining 
enzymatic activity, resulted in complete resistance of cancer cells to MPA. In nude mice 
subcutaneously engrafted with HeLa cells, MPA moderately delayed tumor formation by 
inhibiting cell proliferation and inducing apoptosis. Importantly, we developed a lentiviral 
vector-based Tet-on label-retaining system that enables to identify, isolate and functionally 
characterize slow-cycling or so-called label-retaining cells (LRCs) in vitro and in vivo. We 
surprisingly found the presence of LRCs in fast-growing tumors. LRCs were superior in 
colony formation, tumor initiation and resistance to MPA as compared to fast-cycling cells. 
Thus, the slow-cycling compartment of cancer seems predominantly responsible for 
resistance to MPA. 
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Introduction 
Uncontrolled cell proliferation resulting from cell cycling deregulation is a hallmark of 
cancer. Although aggressive cancers are diverse and heterogeneous, they almost 
universally contain a fast-cycling compartment that can rapidly complete a cell cycle, and 
these cells are primarily responsible for the increase in tumor mass 1. This impressive 
proliferative capacity is, however, dependent on adequate supply of nucleotides. Cellular 
nucleotide synthesis is biochemically complex, but requires various enzymes that can be 
clinically targeted, including Inosine monophosphate dehydrogenase (IMPDH), which is a 
rate-limiting enzyme in de novo synthesis of guanine. The enzymatic activity of IMPDH is 
composed of two separate isoforms, type 1 and 2 2. The IMPDH2 isoform is associated 
with aggressive cancerous disease in experimental cancer 3-6, and related to poor survival 
in osteosarcoma patients 7. Mycophenolic acid (MPA) acts as a nonnucleoside, 
noncompetitive, reversible inhibitor of IMPDH with 5-fold higher potency of inhibiting 
IMPDH2 than IMPDH1. It has been reported to be able to inhibit cancer cell proliferation 
and induce apoptosis in several experimental models of human solid tumors and 
hematological malignancies by depleting guanine nucleotide pools 5, 8-10.  
In the last decade, interest into the importance of cell cycle velocity heterogeneity of 
cancers has increased. Although it was initially thought that cancer cells universally cycle 
and grow faster than normal cells, recently a slow-cycling (largely quiescent) compartment 
has been identified in many tumors, which does not divide frequently but with the capacity 
to generate progeny that can repopulate the fast cycling compartment 11. Functionally, 
these slow-cycling cancer cells appear to be associated with capacity to generate new 
metastases while having superior resistance to therapy 12. Technically, these slow-cycling 
cells are identified by their capacity to retain a pulse label as faster cycling cells lose the 
pulse label at cell division. Thus these cells are indicated with the term label-retaining cells 
(LRCs) 13.  
In this study, we aim to develop a lentiviral vector-based Tet-on label-retaining 
system that enables to identify slow-cycling cancer cells in vivo, which can be 
subsequently isolated for functional characterization. We exploit this system to investigate 
the different sensitivity between fast and slow-cycling cancer cells to IMPDH2 inhibition by 
MPA.  
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Materials and Methods  
Reagents 
Stocks of MPA (AMRESCO LLC, USA) were dissolved in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, St Louis, MO). Doxycycline, Collagenase IV and DNase were purchased 
from Sigma-Aldrich Corporation. Antibodies against IMPDH2, p-Histone3 and Cleaved 
caspase3 were purchased from Abcam Company, Millipore Corporation and Cell Signaling 
Technology, respectively.  
Cell culture 
To investigate the effects of MPA on cancer cells, 7 different cancer cell lines derived from 
various tumor types were cultured. Human hepatoma cell lines HepG2 and HuH7, colon 
adenocarcinoma cell line Caco2, the epithelioid cervix carcinoma cell line HeLa and ovary 
adenocarcinoma cell line SKOV-3 were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (GIBCO Life Technologies). Pancreatic cancer cell lines BxPC3 and PANC-1 
were cultured with RPMI-1640. Both of the mediums were supplemented with 10% (v/v) 
fetal bovine serum (FBS) (Hyclone Technologies), 100 units/mL of penicillin and 100 
µg/mL of streptomycin. All the cells were incubated at 37℃ in a humidified atmosphere 
containing 5% CO2. All the cell lines were confirmed with mycoplasma free and their STR 
genotyping were analyzed at the Department of Pathology, Erasmus Medical Center 
Rotterdam (Supplementary table. 1). 
Lentiviral vector-based Tet-on label-retaining system 
Lentiviral backbone plasmids pLV.EX3D/EF1A-rtTA(M2)-dsRed-Express2 and 
pLV.EX2D/TRE-eGFP were used to pack third generation lentiviral vectors 
(Supplementary Figure S1A). HeLa cells were transduced with both vectors to generate a 
system (HeLa tet-on) that can express a histone 2B-green fluorescent fusion protein 
(Histone-GFP) upon induction by doxycycline. GFP expression in vitro was analyzed from 
week 0 to week 3 by flow cytometry analysis (FACS) and confocal microscope (Zeiss LSM 
510) (Supplementary Figure S1B and S1C). ZenlightEdition software was used to analyze 
confocal microscope images. Cells that maintained GFP expression over this period of 
time were identified as LRCs.  
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For identification of LRCs in vivo, female NOG mice at the age of 8-10 weeks were 
purchased from Taconic Biosciences (Denmark). Animal experiment was performed with 
the approval of the institutional animal ethics committee (Dier Experimenten Commissie, 
Erasmus MC). Mice were breed in Special Pathogen Free (SPF) environment during the 
whole experimental period. Mice were injected subcutaneously with 5×106 HeLa tet-on 
cells. After engraftment (10-15 days), water containing 1 mg/mL doxycycline and 5% 
sucrose has been given for 5 days. Mice were sacrificed at different time points after 
withdrawal of doxycycline. A proportion of harvested tumor samples was fixed with 4% 
paraformaldehyde and embedded in paraffin for subsequent immunohistochemistry. While 
the remaining tumor tissue was dissociated with 5 mg/mL collagenase IV and 2 mg/mL 
DNase at 37℃ for 30min to obtain single cell suspension. Cells were further sorted as 
singlets for separation into Non-LRCs (GFPlowdsRed) and LRCs (GFPhighdsRed) by FACS 
sorter (Supplementary Figure S2). Non-LRCs and LRCs were injected subcutaneously into 
mice (either 1,000 cells or 10,000 cells per injection as appropriate) on four sites in the 
mice. At the same time, two populations of sorted cells were plated for colony formation 
unit assay (CFU) (treated with or without MPA).  
Colony formation assay 
Cells were harvested and suspended in culture medium, yields were quantified through 
counting and plated in 6-well plates (500 cells/well), and then treated with serial dilutions of 
MPA (1, 2, 3, 4 and 5 μg/mL). The control group was supplemented with equal volume of 
PBS. For the cells derived from xenograft tumour, cells were seeded into 12-well collagen 
coating plates and cultured in medium with or without MPA (10 μg/mL). Formed colonies 
were fixed by 70% ethanol and counterstained with haematoxylin & eosin after two weeks. 
Colony numbers were counted and their sizes were measured microscopically through 
digital image analysis. 
MTT assay 
Cells were seeded in 96-well plate, at a concentration of 5×103 cells/well in 100 μL 
medium. Cells were incubated overnight to attach to the bottom of the wells, and then 
treated with serials dilutions of MPA (1, 5, 10, 15, 20, 25 and 30 μg/mL). Cell viability was 
analyzed by adding 5 mg/mL MTT (Sigma-Aldrich, St Louis, MO) and 150 μL DMSO. 
Absorbance was determined using Enzyme mark instrument at the wavelength of 490 nm. 
Analysis of cell cycle 
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Cells (5×105/well) were plated in six-well plates and allowed to attach overnight,  followed 
by application of MPA at the concentrations of 5, 10, 15, 20 and 25 μg/mL for 48 h. Vehicle 
control was performed through the addition of an equal volume of PBS. After 48 h, control 
and treated cells were trypsinized and washed with PBS and then fixed in cold 70% 
ethanol overnight at 4℃. The cells were washed twice with PBS and incubated with 20 
μg/mL RNase at 37℃ for 30 min, and then with 50 μg/mL Propidium Iodide (PI) at 4℃ for 
30 min. The samples were analyzed immediately by FACS. Cell cycle was analyzed by 
ModFit LT 3.0 software.  
 
Analysis of cell apoptosis 
Cell apoptosis analysis was performed by staining cells with Annexin V-FITC and PI. Cells 
(5×105/well) were seeded into six-well plates and incubated at 37℃ in 5% CO2 for 
overnight, then serials dilutions of MPA (5, 10, 15, 20 and 25 μg/mL) were added; whereas 
for vehicle control, an equal volume of PBS was used. After 48 h, all of the cells were 
trypsinized and resuspended in Annexin-binding buffer, and stained with Alexa Fluor 488 
AnnexinV and PI at room temperature for 15 min. Detection of apoptosis was performed 
by FACS.  
Xenograft assays in nude mice 
The xenograft tumor model was performed using nude mice in accordance with current 
prescribed guidelines and under a protocol approved by the Institutional Animal Care and 
Use Committee of Hangzhou Normal University, China. Mice were breed in SPF 
environment during the whole experimental period. Mice were all female and 4-6 weeks of 
age at the time of inoculation, and were subcutaneously inoculated with 5X106 of HeLa 
cells. After 20 hours, mice were divided into 3 groups and were treated with different doses 
of MPA or PBS (240 mg/kg body weight, n = 10; 60 mg/kg body weight, n = 11 and PBS, n 
= 10) 2. MPA was injected via the intraperitoneal (IP) route for 20 consecutive days. Tumor 
formation was monitored through palpation. At day 30 post-engraftment, mice were 
sacrificed and tumors were harvested and macroscopically analyzed. Tumor tissues were 
fixed with 4% paraformaldehyde and embedded in paraffin for evaluation by histology or 
immunohistochemistry.  
Immunohistochemistry 
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Paraffin embedded tumor tissue slides were deparaffined in xylene, rehydrated in graded 
alcohols, and rinsed in PBS supplemented with 0.05% Tween 20. Slides were boiled in 
citrate acid buffer (pH 6.0) for 10 min to retrieve antigen. A 3% H2O2 for 20 min at room 
temperature treatment was used to block endogenous peroxidase activity. The slides were 
incubated in 5% milk-containing blocking solution followed by overnight incubation with 
either a rabbit monoclonal antibody against IMPDH2, a rabbit polyclonal antibody against 
p-Histone H3 or a rabbit polyclonal antibody against cleaved caspase 3, used at a final 
dilution of 1:500, 1:1000, 1:3000 respectively and then counterstained with hematoxylin 
according to routine procedures. As a negative control, the primary antibody was omitted; 
positive controls were taken from other slides that had been successfully stained before. 
IMPDH2, phosphor-Histone H3 and cleaved caspase 3 staining were scored by two 
independent expert observers. The numbers of mitotic cells and cleaved caspase 3 
positive cells were counted in 10 high-power fields. Median numbers of positive cells in 
each of the 10 fields were calculated for each sample of the different groups using a semi-
quantitative assessment. Three categories were used to evaluate the percentages of 
apoptotic cells: < 10% mild; 10% - 50% moderate; > 50% high. The intensity of IMPDH2 
staining was presented by categories: + weak; ++ moderate; +++ strong. 
Statistical analysis  
Statistical analysis was performed by using the nonparametric Mann-Whitney test for 
paired or non-paired data, or the paired T-test using GraphPad InStat software as 
appropriate. A P value < 0.05 was considered statistically significant. 
 
 
Results 
MPA is very effective for inhibiting cancer cell proliferation in fast-
growing cell lines 
A first indication as to how MPA effects on cancer cells relate to cell cycle velocity comes 
from experiments in which we investigated the effects of MPA on cell proliferation and 
colony-forming potential of different cancer cell lines. To this end, 7 different cancer cell 
lines derived from various tumor types were compared. Growth curves show substantial 
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variation in the proliferation rate and colony-forming potential of these cell lines; with in 
general HeLa and Caco2 showing more aggressive behavior as compared to the other cell 
lines (Figure 1). Challenge with MPA inhibited both cell proliferation and colony unit-
forming potential of cancer cell lines, but strikingly fast-growing cell lines are more effected 
by MPA treatment as compared to slow-growing cell lines (Figure 1), indicating that MPA 
mainly affects the fast-cycling compartment.  
MPA inhibited cell proliferation, arrested cell cycling and induced cell 
apoptosis in fast-growing cancer cell line 
To further understand how MPA acts on fast-growing cancer cells, HeLa cells (the most 
sensitive cell line to MPA emerged from our panel of cancer cell lines) were treated with 
clinically relevant MPA concentrations 14 and analyzed in more detail for the effects of 
MPA on cellular expansion, cell cycle, and programmed cell death. MPA counteracted 
HeLa cell proliferation and colony-forming potential in a time- and dose-dependent manner 
(Figure 2A). Indeed, even a relatively low concentration (1 μg/mL) of MPA already 
substantially impeded colony formation; whereas higher concentrations (2-5 μg/mL) 
completely inhibited colony formation. The result reports 322 ± 27 colonies/500 cells were 
formed in untreated, but only 148 ± 27 colonies were formed in 1 μg/mL MPA treated 
groups (mean ± SEM, n = 6, P < 0.01) (Figure 2B). Accordingly, the size of CFU was 
significantly smaller in MPA treated compared to untreated groups (96 ± 5 pixels vs 278 ± 
8 pixels, mean ± SEM, n = 30, P < 0.01) (Figure 2C). Furthermore, MPA dose-dependently 
provoked the G0/G1-phase arrest (Figure 2D). In addition, MPA dose-dependently 
triggered both early and late cell apoptosis (Figure 2E). These data suggest that MPA 
profoundly interferes with the physiology of fast-growing cancer cells and raises questions 
as to how cancers can escape the effects of MPA. 
IMPDH2 is a relevant target for MPA in inhibiting cancer cell growth  
The clinical effects of MPA are presumed to be mediated through inhibition of IMPDH 
enzymatic activity and subsequent inhibition of de novo nucleotide biosynthesis. Although 
two isoforms of IMPDH exist, the type 2 isoform (IMPDH2) exhibits a 5-fold higher 
sensitivity to inhibition by MPA as compared to the type 1 isoform (IMPDH1) 3.  
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Figure 1. MPA inhibited cell proliferation and colony formation of different cancer cell lines. (A) 
Growth curve of seven different cancer cell lines show that HeLa cells grow faster than the other cell lines 
tested (mean ± SD, n = 6). (B) MPA inhibited cell proliferation of all seven cancer cell lines as determined by 
MTT, data shown cells were treated by MPA for 72 h (mean ± SD, n = 5). (C) and (D) MPA inhibited single 
cell colony formation of seven cancer cell lines (mean ± SD, n = 6, ***P < 0.001).  
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Figure 2. MPA counteracts proliferation of a fast-growing cancer cell line. (A) Clinically-relevant MPA 
concentrations, potently inhibit proliferation of the HeLa cell line as assessed by MTT activity (mean ± SD, n 
= 5). (B) Clinically-relevant MPA concentrations impair colony formation of HeLa cells (mean ± SD, n = 6). (C) 
Clinically-relevant MPA concentrations impair colony growth of HeLa cell as determined by image analysis 
(mean ± SEM, n = 30, **P < 0.01). (D) MPA treatment causes G0/G1 phase cell cycle arrest. The left panel 
shows cell cycle phase distribution of a vehicle-treated culture, whereas the middle panel shows cell cycle 
phase distribution in a MPA-treated culture. The right panel shows a quantification of the MPA effects on the 
cell cycle of HeLa (mean ± SD, n = 3. *P < 0.05; **P < 0.01). (E) FACS analysis of cellular apoptosis through 
Annexin-V positivity and PI incorporation. The left panel provides an example of a vehicle-treated HeLa 
culture, whereas the middle panel provides an example of the effects seen following MPA treatment. The 
quantification in the right panel shows statically significant stimulation of both early and late apoptosis in the 
5-25 µg/mL MPA concentration (mean ± SD, n = 3, *P < 0.05; **P < 0.01). 
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IMPDH2 is assumed to be the major target of MPA. Moreover, IMPDH2 is often up-
regulated in cancer 15, suggesting that IMPDH2 is the relevant target for MPA in the 
experiments described above. To substantiate this notion, we employed a lentiviral vector 
expressing an experimentally mutated IMPDH2 (mutIMPDH2) fused to GFP 16, 17. The 
product of this construct has normal IMP dehydrogenase activity but lacks the binding site 
for MPA and thus confers MPA-resistance. Transduction of this vector resulted in 
successful expression of this mutated allele in HeLa cells (Figure 3A). In the CFU assay, 
forced expression of this mutated IMPDH2 provoked resistance to MPA treatment (Figure 
3B and 3C). Furthermore, the mutIMPDH2 cells prevented MPA-induced apoptosis (Figure 
3D). These results are consistent with a key role of IMPDH2 in mediating the effects of 
MPA in our experimentation. 
MPA delayed tumor initiation, inhibited cancer cell proliferation and 
induced cell apoptosis in vivo 
Insight into the effects of MPA on tumor cell in vivo was obtained in experiments, in which 
nude mice were used for subcutaneous engraftment of the HeLa cell line. 20 hours after 
inoculation, mice were intraperitoneally injected with MPA for 20 consecutive days. In this 
xenograft model, treatment of MPA (60 mg/kg body weight) significantly (P < 0.05) delayed 
tumor initiation (Figure 4A). In the 240 mg/kg body weight of MPA treated group, one 
mouse failed to form tumor; while tumor formation also tended to be delayed in the other 
mice (Figure 4B). Thus MPA counteracts growth of experimental tumors in this model. 
Immunohistochemical staining of tumors harvested from these mice demonstrated 
significant down-regulation (P < 0.05) of IMPDH2 at the protein level following treatment 
with MPA (Figure 4C). Concomitantly, MPA inhibited tumor cell proliferation, as shown by 
a significant reduction (P < 0.05) of proliferating cells assessed by the percentage of p-
histone H3 positive cells (Figure 4D). Furthermore, MPA treatment provokes substantial 
apoptosis in the tumor cell compartment, as evidence from the significant increase in the 
percentage of cleaved 
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caspase 3 positive cells (Figure 4E). These results show that MPA counteracts tumor 
growth elicited by a fast-growing cancer cell In vivo. 
 
Figure 3. Forced-expression of a mutated IMPDH2, lacking the MPA binding site, results in resistance 
to MPA. (A) An IMPDH2 variant having normal IMP hydrogenase activity but lacking the MPA binding site 
was fused to a GFP reporter (mutIMPDH2) and expressed in HeLa cells by a lentiviral vector. FACS analysis 
showed robust GFP expression in the transduced HeLa cells but not in mock-transduced cells. Transduced 
cells appear to be resistant to MPA in both colony formation (B) (mean ± SD, n = 6, **P < 0.01) and cell 
proliferation assays (C) (mean ± SEM, n = 30, ***P<0.001). (D) MPA-mediated induction of both early 
apoptotic cells as well as late apoptotic cells is significantly reduced in mutIMPDH2 HeLa cells (mean ± SD, 
n = 3. *P < 0.05; **P < 0.01). 
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Figure 4. MPA delayed tumor initiation, inhibited cell proliferation and provokes tumor apoptosis in 
mice. (A) MPA treatment significantly delays tumor initiation by HeLa cells in nude mice. (B) Following the 
experiment, animals were sacrificed and tumors were harvested. The photograph illustrates the macroscopic 
appearance of the tumors in the respective groups. (C) Immunohistochemical staining of harvested tumor 
tissue sections revealed a significant down-regulation of IMPDH2 protein levels following treatment with MPA. 
(D) Treatment of MPA significantly reduced the percentage of p-histone H3 positive (proliferating) cells in the 
tumors. (E) MPA treatment of HeLa-grafted nude mice significantly increased the numbers of anti-cleaved 
caspase 3 immunoreactive (apoptotic) cells (mean ± SEM, PBS, n = 10; 60 mg/kg, n = 11; 240 mg/kg, n = 9, 
*P < 0.05; **P < 0.01). 
 
 
143 | P a g e  
 
Existence of slow-cycling cancer cells compartment in fast-growing 
tumors 
Substantial evidence indicated that slow-cycling cancer cells can evade therapeutic agents 
and repropagate the tumor 18. In order to identify whether there are slow-cycling cancer 
cells in our experimental system, we established a lentiviral based Tet-on label-retaining 
system that enables us to isolate slow-cycling cells for further functional characterization. 
To this end, cells were transduced with two vectors. One vector expresses a reverse Tet 
trans activator (rtTA), dsRed fluorescent protein and a neomycin-resistance cassette. The 
other vector expresses a Histone-GFP fusion protein driven by a tetracycline response 
element (TRE) and puromycin-resistance gene (Supplementary Figure S1A). Stable cell 
lines can be established by co-transducing with these two vectors and the clones can be 
selected either via drug resistance or by cell sorting based on fluorescence. This 
constitutes a genotoxic free and cell proliferation independent approach to identify slow-
cycling cells. Upon induction by doxycycline, all the cells are labeled with GFP. After 
doxycycline withdrawal, dividing cells lose their GFP signal; whereas quiescent or slow-
cycling cells retain their GFP expression, which thus serves as a label for LRCs (Figure 5A 
and Supplementary Figure S1). 
HeLa cells engineered with Histone-GFPtet-on were subcutaneously engrafted in 
immunodeficient mice (Figure 5B). Once a small tumor was formed, Histone-GFP 
expression was induced by doxycycline in the drinking water of the animal. Following 
doxycycline withdrawal, mice were sacrificed at different time points. As shown by both 
FACS and Immunohistochemical staining, a small population of LRCs was detected in 
tumors (Figure 5C and 5D). Thus we concluded that even fast-growing tumors harbor LRC 
compartment. 
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Figure 5. Identification of slow-cycling cancer cells using a lentiviral label-retaining system. (A) 
Illustration of principle the lentiviral Tet-on Histone-GFP strategy employed. Confocal imaging confirms the 
specific induction of nuclear Histone-GFP expression in HeLa cells upon doxycycline treatment. (B) 
Schematic representation of the experimental approach to identify, isolate and characterize the slow-cycling 
cells, or termed as label-retaining cells (LRCs) in vivo. (C) FACS characterization of Histone-GFP expression 
in transduced HeLa cell during 3 weeks following release from doxycycline induction. (D) 
Immunohistochemical staining of harvested xenograft tumor tissues confirms the presence of nuclear anti-
GFP immunoreactivity in these tissues.  
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Slow-cycling cells are superior in tumor formation and display more 
resistance to MPA 
To functionally characterize LRCs, LRCs and non-LRCs were isolated from HeLa cell-
derived tumors using FACS sorter (Figure 5B and Supplementary Figure S3). Surprisingly, 
ex vivo CFU assay showed that LRCs were significantly more efficient in colony formation 
(non-LRCs: 2.8 ± 1.3 colonies/100 cells; LRCs: 8.1 ± 2.2, mean ± SEM, n = 19, P < 0.001) 
when compared to fast-cycling cells (Figure 6A). Consistently, LRCs are more efficient in 
forming tumors, both with regard to size and number in immunodeficient mice upon 
subcutaneous engraftment (Figure 6B).  
Subsequently, we evaluated the relative sensitivity of LRCs and non-LRCs to MPA. 
Both populations were sorted and colony forming potential was assessed in the presence 
or absence of MPA. Compared with the control groups, treatment with MPA (10 μg/mL) 
significantly inhibited the colony formation efficiency of non-LRCs but not of LRCs (where 
only minor effects were seen; Figure 6C). Thus, slow-cycling cancer cells when compared 
to fast-cycling cancer cells appear more resistant to MPA and may thus constitute the 
MPA-resilient reservoir in cancers.  
Discussion 
IMPDH is a key enzyme in de novo guanine nucleotide biosynthesis and is thus a target 
for oncologic disease. MPA works as a potent IMPDH inhibitor that is used as an 
immunosuppressive drug 3. A phase I trial in patients with advanced multiple myeloma 
showed a positive correlation between clinical responses and depletion of the intracellular 
deoxyguanosine triphosphate levels by mycophenolate mofetil (MMF), the prodrug of MPA. 
MMF was administered up to a maximum dose of 5 g/day, which is 2-3 times higher than 
general use in organ transplantation patients, but was well tolerated in this study 19. In 
renal transplant patients, a tendency towards a lower risk of malignancy in MMF-treated 
patients versus non–MMF-treated has been reported in a large, prospectively conducted, 
observational cohort study 20. However, another  
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Figure 6. Grafted label-retaining cells are superior in tumor initiation and more resistance to MPA. (A) 
The macroscopic appearance of the tumors formed following secondary grafting of LRCs and non-LRCs 
respectively. (B) Colony formation following grafting LRCs and Non-LRCs harvested from xenograft tumor 
tissues (mean ± SEM, n = 19, ***P<0.001). (C) Colony formation by LRCs and Non-LRCs harvested from 
xenograft tumor tissues, when treated with MPA at a concentration of 10 μg/mL (mean ± SEM, n = 17, 
***P<0.001). 
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clinical study in pancreatic cancer failed to show any beneficial effects 21. We found that 
only fast-cycling, but not slow-cycling, cancer cells are sensitive to the inhibitory effects of 
MPA. Thus, dissecting the heterogeneity of cancer may help to understand the distinct 
responsiveness to MPA treatment.  
A unique aspect of this study is the use of a label retaining technique that enables 
to identify and isolate LRCs. Classically, nucleotide analogs, such as 5-iodo-2'-
deoxyuridine and Bromodeoxyuridine, are commonly used to identify LRCs. These agents 
can be used to identify LRCs, but the cells are not able to be isolated for functional study 22. 
Thus, fluorescent-coupled nucleotide analogs were developed for identification and 
isolation of LRCs. However, these agents are not competent for in vivo application 23. 
Although nucleotide analogs were also able to label cells in vivo, subsequent isolation of 
LRCs from the tissue is often a challenge that hampers further functional investigation 22. 
Another major drawback is that most of these labeling methodologies rely on cell division 
to label cells. Therefore, the real quiescent cells in fact cannot be labeled. Consequently, 
the introduction of modified nucleotides into cells profoundly alters the status of the cells 24. 
Integrating lentiviral-based Tet-on cell labeling system has circumstanced these limitations. 
Up on induction of the GFP fluorescent protein, all the cells can be labeled without 
genotoxic effect. It can be used for identification and isolation of slow-cycling cells both in 
vitro and in vivo. In this study, we used a Histone-GFP fusion protein that localized in the 
cell nucleus with prolonged half-life 25. Thus, this technique bears broad implications for 
studying cell cycling. Indeed, we found the existence of slow-cycling cancer cell 
compartment within the fast growing tumors formed by HeLa cells. These cells are 
superior in tumor initiation and more resistant to MPA. We speculate that the existence of 
slow-cycling cancer cells in different patient population may affect the ultimate 
responsiveness of MMF/MPA treatment 19-21.  
IMPDH2 is up-regulated in proliferating cells 26, including in various types of cancer 
cells 27, 28, and exhibits a 5-fold higher (compared to IMPDH1) sensitivity to  
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MPA. Mechanistically, the effect of MPA appears through inhibition of its canonical target, 
IMPDH2. Ectopic expression of a mutated IMPDH2 (mutIMPDH2) largely nullifies the anti-
proliferative effects of MPA. Since IMPDH is the key enzyme in purine nucleotide 
synthesis pathway, we studied the effects of modulating purine nucleotide pool on cell 
growth. Increasing the nucleotide concentration by supplementation of exogenous 
guanosine did not have major effect on cell growth (Supplementary Figure S4). In addition, 
we surprisingly found that supplementation of exogenous guanosine counteracts only to a 
minor extent to the inhibitory effect of MPA (Supplementary Figure S5). Although the anti-
proliferative of MPA is mainly dependent on targeting IMPDH2, depletion of nucleotide 
could only explain part of its mechanism-of-action. 
Interestingly, a recent study has demonstrated a double functionality for IMPDH in 
drosophila. It can also act as a transcription factor in stress conditions that inhibits cell 
proliferation 29. Thus we speculate that IMPDH2 might be a ligand-regulated transcription 
factor and MPA might act as a ligand. Indeed, IMPDH2 is predominantly located in 
cytoplasm in normal condition of cultured HeLa cells, but efficiently translocated into 
nucleus upon MPA treatment (Supplementary Figure S6A). Consistently, a mutated 
IMPDH2 lacking the binding site of MPA was not able to translate into nucleus even with 
treatment of MPA (Supplementary Figure S6B). These results appear to support the 
previous observation in Drosophila cells and our hypothesis. Furthermore it is already 
known that MPA works as a ligand to activate the activity of peroxisome proliferator 
activated receptors, such as PPARγ 30, a critical nuclear receptor on adipocyte 
differentiation. However, gene silencing of PPARα and PPARγ did not affect the sensitivity 
of HeLa cells to MPA treatment, excluding their potential involvement (Supplementary 
Figure S7). The scenario that MPA acts as a ligand for ligand-regulated transcription 
factors to regulate cancer cell growth is certainly interesting and therefore deserves further 
investigation.  
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In summary, this study demonstrated that through inhibiting IMPDH2, MPA was 
capable of constraining the growth of fast-cycling cancer cells. Using a lentiviral Tet-on cell 
labeling technique, we identified slow-cycling cancer cells within the fast-growing tumors 
that are superior in tumor initiation but more resistant to MPA. Thus, it is very necessary to 
develop regimens that can effective target slow-cycling cancer cells. Combining these 
regimens with agents targeting fast-cycling cancer cells, such as MPA, may be a viable 
option in cancer therapy. 
Conclusion 
Slow-cycling cancer cells within fast-growing tumors were identified. These cells, 
compared to fast-cycling cells, were superior in tumor initiation and resistant to IMPDH2 
inhibition by MPA. Thus, simultaneous targeting slow and fast-cycling cells are necessary 
to eradicate cancer. 
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Supplementary Information 
Supplementary Figure 1 
 
Figure S1. Label retaining Hela
tet-on
 cell line expressing histone2B-GFP in a Tet-inducible fashion. (A) 
Plasmids pLV.EX3D/EF1A-rtTA (M2)-dsRed-Express2 and pLV.EX2D/TRE-eGFP were used. (B) and (C) 
GFP retaining condition in vitro could be detected even 3 weeks after doxycycline withdraw. 
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Supplementary Figure 2 
 
Figure S2. Tumor tissue were dissociated into single cell suspension and sorted for Non-LRCs 
(GFP
low
dsRed) and LRCs (GFP
high
dsRed) by FACS. 
Supplementary Figure 3 
 
Figure S3. Non-LRCs and LRCs were injected subcutaneously into mice with cell number of 1.000 and 
10.000 on four sites. Arrows indicate tumor formation. 
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Supplementary Figure 4 
 
Figure S4. Guanosine alone did not significantly affect cell proliferation. (A) CFU appearance and numbers. 
(B) MTT assay. 
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Supplementary Figure 5 
 
Figure S5. Anti-proliferative effects of MPA were partially restored by supplementation of exogenous 
guanosine. (A) and (B) The number of CFU, (C) and (D) The size of CFU were partially restored by 
supplementation of exogenous guanosine during treatment of the HeLa cell line with MPA (mean ± SD or 
SEM, n = 6 or 30, respectively, *P < 0.05; **P < 0.01). 
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Supplementary Figure 6 
 
Figure S6. Cellular localization of IMPDH2 protein. (A) IMPDH2 protein predominately located in cytoplasm, 
but translocate into nucleus upon MPA treatment in HeLa cells. Blue: DAPI nuclear staining. Green: antibody 
against human IMPDH2. (B) A mutated IMPDH2 (fused with GFP) lacking the binding site of MPA was not 
able to translate into nucleus even with treatment of MPA in HeLa cells. Blue: DAPI nuclear staining. Green: 
GFP 
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Supplementary Figure 7 
 
Figure S7. Knockdown of PPARα or PPARγ did not affect the sensitivity of HeLa cells to MPA treatment. (A) 
and (B) Relative mRNA levels of PPARα or PPARγ in HeLa cells transduced with 5 different lentiviral shRNA 
clones, GAPDH was used as an internal reference. (C) Clone 1 (KD1) and 2 (KD2) for each gene were 
selected to perform MTT assay.  
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Supplementary Table S1 
STR genotyping of seven cancer cell lines 
 
The STR match threshold is range from 71% to 94%.  
STR genotyping information comes from the website: http://strdb.cogcell.org/ 
  
STR  Panc-1 BxPC-3 Caco2 HeLa HepG2 Huh7 SKOV-3 
D3S1358 17 14/16 14/17 18/18 15/16 15/15 14/14 
TH01 7/8 9 6 7/7 9/9 7/7 9/9,3 
D21S11 28 29 30 27/28 29/31 30/30 30/31,2 
D18S51 12 12 12 uitval 13 uitval 16/17/18 
Penta_E 7/14 12/14 7 uitval 15/20 11/11 5/13 
D5S818 11/13 11 12/13 12/14 11/13 12/12 11/11 
D13S317 11 11 11/13/14 12/14 9/13 10/11 8/11 
D7S820 8/10 10/13 11/12 8/12 10/10 10/11 13/14 
D16S539 11 9/11 12/13 10/10 12/13 10/10 12/12 
CSF1PO 10/12 13 11 9/10 10/11 11/11 11/11 
Penta_D 14 14 9 8/8 9/13 12/12 12/13 
AMEL X X X XX XY XX XX 
vWA 15 14/18 16/18 16/18 17/17 16/18 17/18 
D8S1179 14/15 13 12/14 uitval 15/16 14/14 14/15 
TPOX 8/11 8 9/11 8/12 8/9 8/11 8/11 
FGA 21 20/21 19 21 22/25 22/22 24/25 
Match 87% 81% 77% 84% 74% 94% 71% 
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CHAPTER 6 
 
 
 
Summary and Discussion 
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The research of stem cells has always attracted tremendous attention, not only because 
they can be utilized as potential therapeutic agents for treating various diseases, but also 
due to their possible participation in the tumor formation and progression. However, both 
of the good and evil aspects for liver stem cells require extensive investigation. The 
present thesis has attempted to demonstrate that how liver stem cells behave in livers in 
physiological homeostasis, upon injury, as well as carcinogenesis (Figure 1).  
 
Stem Cells in Intestine and Liver 
Although the intestine and liver are both endodermal organs, they are highly different in 
biological behavior and function. The intestinal epithelium proliferates every 3-5 days to 
compensate for the loss of functional cells. However, the hepatocytes in human liver 
normally live over 200 days before they are replaced by new cells. Apart from these 
apparent differences, the stem cells from those two organs also behave differently during 
the organ homeostasis and upon injury. 
The intestine harbors a dedicated cycling stem cell population, which is responsible to 
fuel the rapid turnover of intestine. At the bottom of intestinal crypts, LGR5+ cells are 
consistently self-renewing and generating rapidly dividing daughter cells 1. In contrast, liver 
LGR5 cells are an intermediate stem cell population which not present in homeostatic 
period but only emerged upon liver injury (Chapter 2). 
In the intestine, the quiescent/slow cycling label retaining cells (LRCs) occupy the +4 
position from the crypt base. Those label retaining cells are marked by polycomb complex 
protein 1 oncogene (BMI1) 2, leucine-rich repeats and immunoglobulin-like domains 
protein 1 (LRIG1) 3, mouse telomerase reverse transcriptase (mTERT) 4, RNA-binding 
protein MEX3A (MEX3A) 5 or Hop homeobox (HOPX) 6. Upon the depletion or dysfunction 
of LGR5 stem cells, those quiescent stem cells will be activated to repopulate the stem cell 
niche. The function of quiescent stem cells in intestine is more like a distinct reserve stem 
cell population.  
Similar to intestine, the liver label retaining cells also express Lrig1, mTert and Mex3a 
(Chapter 2). Unlike intestine, the label retaining cell is not a subpopulation or backup of 
LGR5 stem cell. The liver label retaining cells present in the homeostatic liver, retaining 
the GFP label over 1 year, which can expand and further differentiate into functional cells 
in vitro. Interestingly, LRCs give birth to Lgr5 stem cell, as well as other progenitor/stem 
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cell populations, including SOX9 and CD44 cells. This is also consistent with our finding 
that LGR5 can be absent in the initiation and expansion of liver organoids (Chapter 2). 
These results imply that liver contains a hierarchical structure that quiescent stem cells 
could maintain the homeostasis and respond to injury by give rise to a multiply 
stem/progenitor cells. However, innovative techniques should be developed for identifying 
the quiescent stem cells in human liver, thus further providing effective therapeutic agents 
for future regeneration medicine.  
 
LGR5 Marks Cancer Stem Cell and Represents a New Therapeutic Target in Liver 
Cancer 
In colon/intestine, LGR5 has been reported as the most important marker for normal stem 
cell, as well as the tumor initiating cells 1, 7-11. In Chapter 2, we have illustrated that LGR5 
marks proliferative stem cells in the liver that are triggered by tissue injury. Thus, we 
further investigate the existence and function of LGR5 cells in liver tumor. 
Our study demonstrated that LGR5 cells appear in the DEN induced liver tumors. The 
percentage of LGR5 cells was significantly higher in tumor proper compared to the tumor 
surrounding, as well as the frequency observed in healthy or acute/chronically injured 
livers (Chapter 4). To further demonstrate the function of LGR5 cells, we established a 
organoid culture system from primary liver tumors (Chapter 3). Employing this model, we 
observed that tumor LGR5 cells have stronger in vitro organoid initiation ability and in vivo 
tumor initiation capability. We also revealed that LGR5 positive cells were more resistant 
to treatment, compared to LGR5 negative cells. More interestingly, the ablation of the 
LGR5 expressing cells in liver tumor would impede the in vivo tumor growth.  
Because cancer stem cells are highly tumorigenic and treatment-resistant, several 
pharmaceutical companies have started programs aiming at eliminating the cancer stem 
cell population. The main strategy involves 1) inhibiting cancer stem cell related key 
pathway, including WNT and NOTCH pathway12; 2) targeting quiescent cancer stem cells 
by an anti-CD36 antibody13; 3) using antibody-drug conjugates to ablate cancer stem cells 
11. In the colon and the intestine, LGR5 has been identified as a potential cancer therapy 
target 9-11. The anti-LGR5-antibody-drug conjugates have been reported to target the 
LGR5 expressing cells in intestinal cancer effectively and further impede the growth of 
tumor, without unacceptable disturbance of the function of normal LGR5 stem cells 11. 
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Thus, It will be of particular interest to further study targeting liver LGR5 cancer stem cell 
based treatment.  
 
Figure 1. Dynamics of Stem Cells in Liver Homeostasis, Injury and Carcinogenesis 
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Perspectives 
 Long-term label retaining cells represent a quiescent stem cell pool in the liver. It is 
maintained during liver homeostasis and respond to liver injury by giving rise to 
different stem/progenitor cells, including LGR5, SOX9 and CD44 positive cells. 
Likely, a combination of multiply stem/progenitor cells, rather than a single 
proliferative stem cell population, contributes to tissue repair in response to injury. 
 
 LGR5 cells are present in liver tumor and represent a cancer stem cell population. 
Targeting LGR5 cancer stem cells provides a novel avenue for combating liver 
cancer. Extensive investigation is warranted to further develop effective therapies 
that can kill the cancer stem cells and prevent the tumor re-growth/recurrence. 
Considering the heterogeneous background of liver cancer, multi-target-based 
therapies should also be further investigated.  
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Multipotente stamcellen zijn cellen die ongespecialiseerd kunnen blijven en door deling 
hun aantal kunnen vermeerderen, maar die ook zich (tot een beperkt aantal) 
gespecialiseerde celtypes kunnen differentiëren. Ze zijn essentieel bij het in stand houden 
van de grootte van organen door afgedankte cellen te vervangen en spelen een 
belangrijke rol bij regeneratie na beschadiging. De hoop dat leverstamcellen bij kunnen 
dragen aan gecontroleerd herstel van beschadigde levers in een klinische setting bestaat 
al lang. Daarnaast bestaat het vermoeden dat leverkanker ontstaat uit zogenaamde 
kankerstamcellen en dat het uitschakelen van leverkankerstamcellen een nieuwe aanpak 
zou kunnen vormen bij het bestrijden van deze (in het geval van gemetastaseerde ziekte) 
ongemeen dodelijke en therapieresistente ziekte. In dit proefschrift probeer ik deze 
leverstamcellen beter te begrijpen en op deze wijze leverstamcel-gerichte therapie in het 
verschiet te brengen. De betrokken vragen die ik mij in dit proefschrift stel werk ik uit in 
hoofdstuk 1. 
In haar algemeenheid kan men zeggen dat stamcelcompartimenten in de lever anders 
lijken dan in de (dunne) darm. Beide organen delen een gemeenschappelijke embryonale 
oorsprong in dat zij alle twee ontstaan uit de endodermale kiemlaag, maar de fysiologie 
van beide organen is erg verschillend. De darm is een abortieve structuur, die blootstaat 
aan extreme mechanische en microbiologische belasting. De darm reageert op deze 
belasting door haar absorbtieve epitheel elke twee tot vijf dagen volledig te vernieuwen. 
De geassocieerde proliferatieve last wordt gedragen door het zogenaamde LGR5+ 
celcompartiment, dat dan ook snel deelt en haar onmiddellijke nakomelingen, in de 
crypten van de darmen. In hoofdstuk 2 bekijk de aard en functie van het LGR5+ 
celcompartiment in de lever. De lever is een schijnbaar solide orgaan, dat bestaat uit 
duizenden kleine celformaties, van 1 mm doorsnede, die het bloed verwerken en een 
cruciale rol speelt in de biochemische homeostase van het lichaam alsmede het ontgiften 
van het bloed. Levercellen moeten naar schatting in gewone omstandigheden na 
ongeveer tweehonderd dagen vernieuwd worden. In mijn proefschrift toon ik aan dat de 
gewone gezonde lever niet een substantieel LGR5+ stamcelcompartiment bevat. Wordt de 
lever beschadigd, bijvoorbeeld door een insult met xenobioticum zoals 
koolstoftetrachloride, dan verschijnt een LGR5+ compartiment in de zich regenererende 
lever, die het herstel van het orgaan lijken te ondersteunen. Men kan zich voorstellen dat 
bij leverziekten ondersteuning van de LGR5+ positieve cel een positief effect zal hebben 
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op het herstelproces. Uit vervolg experimenten bleek echter dat het belang van deze 
LGR5+ cellen in dit opzicht waarschijnlijk beperkt is. 
In de darm wordt het snel delende LGR5+ compartiment onderhouden door een dieper 
stamcel compartiment, dat juist niet deelt. Als LGR5+ cellen verloren gaan (denk 
bijvoorbeeld aan chemotherapie of stralingsschade, maar ook huis, tuin en keuken verlies 
van deze cellen tijdens het normale leven) dan worden deze diepe stamcellen wakker en 
genereren ze nieuwe snel delende LGR5+ cellen. Deze diepe stamcellen zijn dus een 
reservoir waar het LGR5+ compartiment uit kan putten als dat nodig is. Ik kon echter 
vaststellen dat in de lever LGR5+ stamcellen noodzakelijk nog voldoende zijn bij het 
herstel van de lever na schade. Wel bevat de een diep slapend stamcelcompartiment dat 
aan de top staat van een complexe stamcel hiërarchie van dochter stam- en 
progenitorcellen dat weliswaar in staat is om nieuwe LGR5+ cellen te genereren, maar ook 
vele andere nakomelingen heeft. Deze populatie van diepe, slapende stamcellen lijkt dan 
ook het meest interessant bij het denken over regeneratieve geneeskunde met betrekking 
tot de lever. 
Zulke cellen bleken ook interessant te zijn in de context van leverkanker. Ik onderzocht in 
welke mate LGR5+ cellen aanwezig waren in levertumoren en ik kon vaststellen dat 
leverkanker veel meer van dergelijke cellen bevatte in vergelijking tot het gezonde weefsel 
naast de kanker (hoofdstuk 4). Ook waren deze LGR5+ cellen veel talrijker in de tumor 
dan gezien werd in gezonde levers of zelfs levers met acute of chronische ontsteking. Dus 
terwijl LGR5+ cellen niet noodzakelijk zijn voor het oncologisch proces in de lever, zijn ze 
er wel mee geassocieerd. Deze bevinding riep dan ook vragen op of de LGR5+ in de lever 
wellicht dan ook een rol zouden spelen in de verklaring voor waarom leverkanker zo 
ongewoon chemotherapieresistent is of in ieder geval een factor in de progressie van 
leverkanker zouden kunnen zijn. Data uit hoofdstuk 3 lijken een dergelijke these te 
ondersteunen. Hier onderzocht ik organoiden (dit zijn kleine in de kweekschaal groeiende 
structuren die de meeste eigenschappen van het oorspronkelijke weefsel behouden en 
daarom uitstekend geschikt zijn voor wetenschappelijke experimentatie). Ik vond dat 
organoiden afgeleid van LGR5+ cellen vaker succesvol tot stand kwamen, dat zij vaker 
echte tumoren konden maken en dat zij meer resistent zijn tegen behandeling dan 
organoiden afgeleid van andere cellen. De verleiding is dus groot om deze LGR5+ cellen 
te zien als potentieel doelwit voor verbeterde behandeling van leverkanker. 
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In een laatste experimenteel hoofdstuk (hoofdstuk 5) probeer ik op grove wijze te testen 
in welke verschillende subpopulaties van leverkanker inderdaad echt belangrijk zijn in het 
verklaren van therapie resistentie. Om dit te bereiken, sorteerde ik kankercellen in twee 
groepen: een groep langzaam deelde en een groep die snel deelde. Ik zag dat de 
langzaam delende groep veel minder goed op therapie reageerde en ook dat deze groep 
veel gevaarlijker was wat betreft uiteindelijke grootte van de tumor. Het is dus inderdaad 
zo dat er verschillende groepen kankercellen zijn met verschillende relevantie voor het 
oncologisch proces. 
Ik bediscussieer al deze data in hoofdstuk 6. Samengevat, kan ik stellen dat mijn data in 
belangrijke mate een hiërarchie in stamcel compartimenten in haar algemeenheid, maar 
ook in oncologische ziekte, ondersteunen waarvan de precieze onderlinge  interactie de 
reactie op een insult (hetzij chemische schade voor het stamcelcomplex in gezonde 
organismen, hetzij de reactie op chemotherapie bij kanker) bepaald. Met deze kennis zou 
het mogelijk moeten zijn om meer doelgerichte therapie te ontwikkelen voor het 
behandelen van zowel leverschade alsook leverkanker, althans ik hoop met dit proefschrift 
daartoe een eerste aanzet te hebben gegeven. 
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To Martijn, you are a smart and happy person. It is really fun to play the game of The Werewolves 
of Miller's Hollow with you and other colleagues during the camping. Those are really happy 
memories to me. And also congratulation to your defense. Wish the best to your future. 
To Suk Yee, you are such a smart and happy girl. It is such a unique feeling to talk with you, 
because we can switch the language between English and Chinese. You just like a person who 
can bring sunshine to friends. I will just become happy during the talking with you. You definitely 
will have a brighter future and wish you can find your Mr. Right as soon as possible.  
To Anthonie. You are always so happy no matter in the lab or in the parties, And it is so cute to see 
you and your son have the same hairstyle. Wish the best for your family.  
To Kim, you are such a nice person. For me, it will just be happy when see you in the lab. I really 
enjoy the time when you plan and describe your future with you family. Hope I can have the 
chance to visit you when you finally move to your dreamland.  
To Petra, you are such an elegant and nice lady. Maybe you do not know this, but actually you are 
an idol for me. You really have a lifestyle which I admire so much. I really like the Rotterdam Tour 
you give, playing piano with your daughter and etc. Hope all the best for your future.  
To Monique (de Beijer), my neighbor in the lab. You like to sit in the left side of the flow cabinet and 
I love the right side. And we always work until late in the night. That’s why we are always neighbors 
in the lab. You are so smart and work so hard. I could feel the passion and unlimited energy from 
you for the scientific research. Wish the best to your bright future.  
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To Floris, my friend, also my neighbor in the lab as well as in the office. You are so smart and 
always so happy. You really make good plan for your life, both for career and family. I really wish 
the best for your future.  
To Ruby, I am really happy to hear that there will be a new PhD student in your group working on 
liver organoid. The feeling is just: yeah, finally, I will have an ally. You are a smart and active 
person. And I am lucky to work together with you. Wish you have a sweat, lovely weeding soon 
and as well as a bright future.  
To Lisanne, I really feel that life only gives you with all the good, but not any bad. You are smart, 
beautiful, energetic and elegant. Wish all the best to you. 
To Vincent, you always work so hard. I definitely believe that you will become an outstanding 
doctor in the coming days. Wish all the best to you.  
To Shanta, thank you for sharing so much precious experience in IHC/IF. Besides your help from 
your expert area, you also help me a lot in the first 1-2 years. Because I was very shy initially, you 
are always open to talk with me. That’s really helped me to adjust to the new environment, 
especially in the first year of my PhD. 
To Raymond and Leonie, thank you for giving me so so so much help. Whenever we have different 
types of problems/emergencies/super emergencies, you always can help me out. Give my best 
wishes to you and your entire family. 
To Patrick, you are really a nice, gentle, helpful and optimistic person. Wish all the best to you. 
To Kelly, we are familiar with each other because we are both working on organoid and mice. Our 
style is like: Yes, I am on the way to the EDC. Oh yes, I am in the middle of passaging organoids. 
And you are always just a hero to save my organoid out of danger, because there are always some 
components running out, which I can borrow from you. You are really a sweat and nice girl. Wish 
all the best to your future.  
To Natasha, every time when I see you in lab, I just feel happy. To me, You are a girl full of 
sunshine and energy. You also belong to the “team organoid”, which enables us to see each other 
a lot on weekends, different holidays, early in the morning and late in the night. Wish all the best to 
you.  
To Marla, thank you so much for helping me with the b-catenin staining. Wish the best to you.  
To Pauline, you inspired me a lot. For me, it is already so difficult to handle all the scientific issues. 
But you need to take care both of the career and family. Wish all the best to you and your entire 
family.  
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To Jan, you are always so happy, gentle and helpful. The feeling is just like: you give the world 
with love and the world return back to you also with love. Really looking forward to meet you lovely 
wife and children. Wish all the best to you and your entire family.  
To Buddy, thank you so much for helping us with the ordering all the time. You are always so 
patient and helpful. Wish all of the best to you. 
To Thijmen, you are really a gentleman. Although we did not have so many chances to talk, I heard 
a lot about you from Kan. She mentioned that you kindly taught her pronunciation, which 
impressed me a lot with your warm heart. Wish you the best to your future career.  
To Gulce, you are not only smart but also hard-working. Almost every time when I work until late, 
you are still in the lab. Wish all of the best to you and your future.  
To Sonja, thank you for giving me so much precious suggestions during our weekly GIO meeting. I 
learned so many things from you. Although we work in different areas, you are indeed an idol for 
me. You are energetic, smart and beautiful. Wish all the best to you and your future.  
To Gertine, thank you so much for your help on my experiments. Wish all the best to you.  
To Paula, thank you for teaching us how to pitch a tent. I really enjoy those fantastic camping 
moments. Wish all the best to you and your entire family.  
To Lauke, you will definitely become a good doctor & scientific researcher in the future. Because 
you are smart and also work so hard. no matter it is Weekend, 10 p.m. or Christmas day, you can 
always find Lauke in the lab or in the office. I definitely believe that you will have a brighter future.  
To Noe, you are smart and also work so hard. Plus, I am really interested that, how can you adapt 
to the weather in Rotterdam as a Spainish? This question really bothers me for a long time. Give 
my best wishes to your PhD and future.  
To Shaojun, I am really impressive by your dream about “吃软饭”. Wish your dream will come true 
as soon as possible (just kidding). You are a polite, smart and funny person. I believe that you 
definitely will have a brighter future.  
To llknur, you are really a sweat and nice girl. You give me so much encouragement. Hope we can 
cooperate some day in the future. Give my best wishes to you.  
To Michiel (Mommersteeg), I really enjoy the trip to the Beer festival. Now I have the feeling that: it 
is more easy to make friends with Dutch people with beer around (For our Chinese people, it is in a 
restaurant).  
To Jorke, you also belong to that kind of people who bring sunshine around you. You are always 
so happy and full of energy. Wish all the best to your future.  
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To Yik, another member of “team organoid”. You are a sweat and beautiful girl. Wish all the best to 
your future. 
To Manzhi, you really know what you want and also know how to achieve you target. I learned a lot 
from you. You will definitely have a bright future.  
To Liu Menggang师兄, you just like an older brother to us. You are a good doctor and also a good 
husband. Wish all the best to you and your entire family. 
To all the colleagues from EDC, Ingeborg, Eva, Vincent, Miranda, Jennifer, Charlotte, Sabine, 
Henk (Dronk), Michelle, Ineke and Dr. Mathieu Sommers. Thank you so so much. You gave me so 
many help for the past five years. All the best wishes to you.  
All the co-authors, thank you for the contribution to my thesis and to the journal publications. 
I would like to give my great thanks to the financial support from the China Scholarship Council. 
All MDL members to those who have left and who are present, Professor Hugo de Jonge, Hanneke, 
Andrea, Andre, Thomas, Martine (Meulemans), Frances, Jasper, Ksenia, Dowty, Wouter, Janine, 
Diahann, Wendy, Gijs, Alexander, Kateryna, Kairong, Hakim, Cynthia, Emmeloes, Kostas, Eelke, 
Renee, Henk, Rachid, Ben, Terry, Aniek, and so on. I want to thank you for helping me during the 
five years. I have indeed enjoyed my time with you in the lab. Best wishes to all of you! 
 
To 酷爱美食且酷爱推荐美食同时热爱科研的展民、我感觉是万能的无敌美少女丹莉莉，直爽美丽智
慧的目前已晋级为额娘的黄玲，超级会在狼人杀中伪装自己的同伟、稍微有点神秘但是超级温暖且
睿智的侯珺，南半球一哥的优秀毕业生长斌、喜欢并擅长摄影的吴斌、无敌潇洒且成功转行的潇磊，
帅气幸福的未来之星文浩以及文浩幸福之来源之聪慧小美女瑶瑶，集智慧于美貌于一身的且已订婚
的无敌美少女高雅、另外一个集智慧于美貌于一身的且居然坚持六点起床的高文、智慧超群且号召
力无敌的刘凡老师、无敌且貌美的请务必收下我的膝盖的辣妈温蓓、智慧青春美少女小俊、温柔睿
智大美女陈思，宅且智慧着的月光族魁魁（开销巨头为吃且居然不胖）、绝对是加班 no.1 大半夜可
以在 EMC找到的平臻、优秀毒舌且理解不了为啥还是单身的鲁涛、热爱且会生活的白冠男、温柔小
甜心王璐，总是很开心的徐笑非，绝对学霸的活泼美少女张旭熙，目前口头禅是我们开公司吧的美
女若愚、睿智但是好久不见的凯音、可爱又美丽的睿智小少女陈金鸾，同门师弟晓路，由于“it’s ugly”
的故事一战成名的周頔（di），永远会被国影说服或者怎么都没有办法说服国影的唐颖、如果不是在
跑步就是在去健身路上的健康美少女波波以及其他可爱的朋友们，很荣幸可以遇到如此优秀的你们，
过去的岁月充盈着我们的笑語晏晏，愿大家的未来幸福美好，我们友谊长存。 
To 刘敏和云宝，虽然我们不在一个国家，但是你们永远是我遇到任何苦难和收获喜悦的时候，第一
时间想倾诉和分享的人。你们使我更坚强。 
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To 我的未婚夫李海鑫。谢谢你一直陪着我，给于我坚持下去的动力。过去的五年对于我们来说是艰
难的。但是同时又是很有收获的。你的陪伴和鼓励，使得我的科研之路变的没有那么的漫漫无绝期。 
最后也是最重要的是，感谢我最亲爱的爸爸妈妈。是你们给了我内心最深处的坚持下去的力量。科
研之路非常坎坷，但是因为你们，我从来就没有想过要放弃。没有你们，就没有我。我爱你们，我
爱你们。 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
